Page last updated: 2024-11-04

doxazosin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3157
CHEMBL ID707
CHEBI ID4708
SCHEMBL ID34111
MeSH IDM0026251

Synonyms (110)

Synonym
doxazosinum
doxazosina
2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
CHEBI:4708 ,
doxazosine
2-{4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine
BRD-A13188892-066-03-3
uk-33274
2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-bis(methyloxy)quinazolin-4-amine
BSPBIO_000875
OPREA1_259518
PRESTWICK3_000858
BPBIO1_000963
IDI1_003732
PRESTWICK2_000858
LOPAC0_000474
doxazosin [inn:ban]
uk 33274
doxazosine [french]
piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)-
doxazosinum [latin]
doxazosina [spanish]
CHEMDIV2_005017
74191-85-8
doxazosin
C06970
DB00590
1-(4-amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin
1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin
PRESTWICK1_000858
PRESTWICK0_000858
SPBIO_002796
NCGC00089775-02
AC-11062
HMS2090C20
NCGC00018158-06
c02ca04
CHEMBL707
HMS1383E01
L000738
doxazosin (inn)
D07874
cardura xl (tn)
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone
AKOS001681453
cpd000097306
A838054
[4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl]-[(3s)-2,3-dihydro-1,4-benzodioxin-3-yl]methanone
NCGC00018158-02
NCGC00018158-05
NCGC00018158-03
HMS3259N21
methanone, [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl](2,3-dihydro-1,4-benzodioxin-2-yl)-
2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
EN300-53055
unii-nw1291f1w8
ec 616-059-6
(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(2,3-dihydro-1,4-benzodioxin-2-yl)methanone
nw1291f1w8 ,
uk 33,274
bdbm86731
cas_74191-85-8
CCG-118218
FT-0630831
NCGC00018158-08
S5782
gtpl7170
uk-3327427
HMS3372L09
2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxy-3,4-dihydroquinazolin-4-imine
AKOS017343634
BRD-A13188892-066-13-2
doxazosin [inn]
methanone, (4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl)(2,3-dihydro-1,4-benzodioxin-2-yl)-
(4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl)(2,3-dihydro-1,4-benzodioxin-2-yl)methanone
doxazosin [mi]
(+/-)-doxazosin
doxazosin [who-dd]
doxazosin [vandf]
1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazine
137888-77-8
CS-1831
HY-B0098
NC00685
1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazine
SCHEMBL34111
(4-benzylmorpholin-2-yl)-aceticacid
piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]-
DTXSID7022964 ,
(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanone
doxazosin; 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazine; 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazoline; uk-33274
SBI-0050459.P002
(rs)-2-{4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine
Q419939
BCP12228
SDCCGSBI-0050459.P003
HMS3886J03
NCGC00018158-20
supress
NCGC00018158-11
nsc768145
nsc-768144
nsc768144
nsc-768145
ZCA19185
AS-77104
piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]-, (s)-
2-(4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl)-6,7-dimethoxyquinazolin-4-amine
dtxcid402964
doxazosinum (latin)

Research Excerpts

Overview

Doxazosin (Doxa) is an α1-selective adrenergic receptor (ADR) antagonist. It is widely used, alone or in combination, to treat high blood pressure, benign prostatic hyperplasia symptoms, and recently has been suggested as a potential drug for prostate cancer prevention/treatment.

ExcerptReferenceRelevance
"Doxazosin (Doxa) is an α1-selective adrenergic receptor (ADR) antagonist widely used, alone or in combination, to treat high blood pressure, benign prostatic hyperplasia symptoms, and recently has been suggested as a potential drug for prostate cancer prevention/treatment. "( Orally applied doxazosin disturbed testosterone homeostasis and changed the transcriptional profile of steroidogenic machinery, cAMP/cGMP signalling and adrenergic receptors in Leydig cells of adult rats.
Andric, SA; Janjic, MM; Kostic, TS; Stojkov, NJ, 2013
)
2.19
"(±)Doxazosin is a long-lasting inhibitor of α1-adrenoceptors that is widely used to treat benign prostatic hyperplasia and lower urinary tract symptoms. "( Stereoselective binding of doxazosin enantiomers to plasma proteins from rats, dogs and humans in vitro.
Kong, DZ; Li, Q; Ren, LM; Sun, JA; Yin, ZW; Zhang, JH; Zhang, W; Zhen, YQ, 2013
)
1.31
"Doxazosin is a racemic mixture of (-)doxazosin and (+)doxazosin that is currently used as an add-on therapy for hypertension. "( (-)Doxazosin is a necessary component for the hypotensive effect of (±)doxazosin during long-term administration in conscious rats.
Kong, DZ; Li, Q; Ren, LM; Wang, DK; Wang, M; Zhao, J; Zhao, Y; Zhen, YQ, 2014
)
2.47
"Doxazosin is an α1 adrenergic receptor blocker that also exerts antitumor effects. "( The antihypertension drug doxazosin inhibits tumor growth and angiogenesis by decreasing VEGFR-2/Akt/mTOR signaling and VEGF and HIF-1α expression.
Dong, SM; Kim, BR; Kim, DY; Lee, SH; Park, MS; Rho, SB, 2014
)
2.15
"Doxazosin is an α(1)-adrenergic receptor antagonist for the treatment of high blood pressure and benign prostatic hyperplasia. "( Novel anti-inflammatory effects of doxazosin in rodent models of inflammation.
Cheung, PH; Ciallella, J; Saha, S; Tung, D, 2013
)
2.11
"Doxazosin is an effective treatment for patients with hypertension, benign prostatic hyperplasia (BPH) and the two comorbidly. "( Effect of doxazosin GITS on blood pressure in hypertensive and normotensive patients: a review of hypertension and BPH studies.
Kirby, RS; Lund-Johansen, P, 2003
)
2.16
"Doxazosin GITS is a safe agent which can reduce cardiovascular risk."( Doxazosin GITS trough to peak ratio and 24-hour blood pressure monitoring in the management of hypertension in renal transplant patients.
Grinyó, JM; Ibernón, M; Martínez Castelao, A; Moreso, F; Rama, I; Sanz, V; Sarrias, X, 2003
)
2.48
"Doxazosin mesylate is an alpha1-adrenoceptor antagonist that was used to treat hypertension until a major study (ALLHAT; Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial) showed that it increased the risk of progressing to heart failure. "( After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia.
Doggrell, SA, 2004
)
2.13
"Doxazosin is a potent reducer of the symptoms in the treatment of the BPE, enhancing urinary flow and reducing DCD in the first place. "( [Analysis of doxazosin efficacy in the treatment of the benign prostatic enlargement].
Aganović, D; Aganović, K; Prcić, A, 2004
)
2.14
"Doxazosin is a quinazoline-based compound acting as an alpha-1-adrenergic inhibitor shown to induce apoptosis in prostate cancer cell lines via an alpha-1-adrenergic receptor-independent mechanism. "( Doxazosin induces apoptosis in LNCaP prostate cancer cell line through DNA binding and DNA-dependent protein kinase down-regulation.
Arencibia, JM; Bonnin, A; Del Rio, M; Lemoine, NR; Lopes, R; López-Barahona, M, 2005
)
3.21
"Doxazosin is an antihypertensive agent with largely unknown effects on arterial stiffness and vasodilation. "( Add-on therapy with doxazosin in patients with hypertension influences arterial stiffness and albuterol-mediated arterial vasodilation.
Adamska, K; Guzik, P; Krauze, T; Milewska, A; Wykretowicz, A; Wysocki, H, 2007
)
2.11
"Doxazosin mesylate is a selective alpha-adrenoreceptor antagonist for the treatment of hypertension and benign prostatic hyperplasia. "( Pharmacokinetics of doxazosin gastrointestinal therapeutic system after multiple administration in Korean healthy volunteers.
Chun, IK; Gwak, HS; Kwon, YH; Yoon, SJ, 2007
)
2.11
"1 Doxazosin is a quinazoline derivative, related to prazosin, recently developed for the treatment of hypertension. "( A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects.
Elliott, HL; McLean, K; Meredith, PA; Reid, JL; Sumner, DJ, 1982
)
1.21
"Doxazosin is a long-acting alpha 1-adrenoceptor antagonist structurally related to prazosin and terazosin. "( Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.
Fulton, B; Sorkin, EM; Wagstaff, AJ, 1995
)
3.18
"Doxazosin is a selective alpha 1 antagonist with a long half-life and gradual onset of action, which make it suitable for once-daily treatment."( Profile of doxazosin in patients with benign prostatic hyperplasia.
Janknegt, RA, 1995
)
1.4
"Doxazosin is an antihypertensive drug that gives rise to 6- and 7-hydroxydoxazosin during hepatic metabolism. "( Doxazosin treatment and peroxidation of low-density lipoprotein among male hypertensive subjects: in vitro and ex vivo studies.
Arnstad, JE; Brude, IR; Drevon, CA; Nenseter, MS; Valnes, KN; Viken, K, 1999
)
3.19
"Doxazosin is an effective antihypertensive agent when used in combination with agents from other antihypertensive classes in patients"( A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT).
Guthrie, RM; Siegel, RL, 1999
)
1.29
"Doxazosin is a selective alpha1-adrenoceptor-blocking anti-hypertensive agent and has a favorable impact upon lipid metabolism."( Effect of doxazosin on the size of LDL particle in the type 2 diabetic patients with hypertension.
Gotoh, T; Hinata, T; Matsui, J; Murakami, H; Ogawa, Y; Suda, T; Tamasawa, N; Zhi, GJ,
)
1.26
"Doxazosin is a long acting alpha(1)-adrenoceptor antagonist, used in the treatment of essential hypertension and/or benign prostatic hyperplasia (BPH)."( Doxazosin, an alpha1-adrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets.
Jagroop, IA; Mikhailidis, DP, 2001
)
2.47
"Doxazosin is a cost-effective agent when included in a combination therapy in the treatment of hypertension in the diabetic populations of the UK and Italy."( The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy.
Arikian, S; Bustacchini, S; Casciano, J; Casciano, R; Doyle, J; Kim, R; Kopp, Z; Marchant, N, 2001
)
1.33
"Doxazosin (dox) is a clinically effective alpha-adrenergic antagonist used in the treatment of symptomatic benign prostatic hyperplasia (BPH)."( Effect of doxazosin on rat urinary bladder function after partial outlet obstruction.
Das, AK; Eagen, G; Leggett, RE; Levin, RM; Whitbeck, C, 2002
)
1.44
"Doxazosin is a postsynaptic alpha-1 adrenoceptor blocker suitable for once a day treatment regime."( [Doxazosin for the treatment of arterial hypertension].
Buzzaccarini, F; Casolino, P; Giusto, M; Mozzato, MG; Pessina, AC; Rubino, N; Semplicini, A; Serena, L; Valle, R, 1990
)
1.91
"Doxazosin is a once-daily, long-acting, selective alpha 1-adrenergic inhibitor that is effective for the treatment of essential hypertension."( Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension.
Pool, JL, 1987
)
1.28
"Doxazosin is a competitive inhibitor of norepinephrine at alpha 1 adrenoceptors on vascular smooth muscle, where it blocks vasoconstriction. "( Effects of alpha 1 inhibition on renal blood flow and sympathetic nervous activity in systemic hypertension.
Wilner, KD; Ziegler, MG, 1987
)
1.72
"Doxazosin is an effective hypotensive agent with beneficial effects on serum lipid levels."( A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension.
Black, H; Nash, DT; Reeves, RL; Schonfeld, G; Weidler, DJ, 1987
)
1.24
"Doxazosin is an effective, well-tolerated, once-daily antihypertensive agent; it is comparable with terazosin but at a lower daily dosage."( Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin.
Hayduk, K; Schneider, HT, 1987
)
1.29
"Doxazosin is a long-acting selective alpha 1-adrenoceptor antagonist structurally related to prazosin. "( Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.
Brogden, RN; Young, RA, 1988
)
3.16
"Doxazosin is a drug with good antihypertensive efficacy and is well tolerated as monotherapy and in combination with beta-blockers, thiazide diuretics, angiotensin converting enzyme inhibitors, and various combinations of these drugs.(ABSTRACT TRUNCATED AT 250 WORDS)"( Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy.
Rosenthal, J, 1988
)
1.25
"Doxazosin is a selective alpha 1-inhibitor for the reduction of calculated coronary heart disease (CHD) risk in hypertensive patients. "( Doxazosin versus atenolol: a randomized comparison of calculated coronary heart disease risk reduction.
Guerrasio, E; Mazzola, C, 1988
)
3.16
"Doxazosin is a long-acting selective alpha 1-adrenoceptor antagonist which has been shown to be effective and well tolerated in the treatment of hypertension given in once-daily doses as monotherapy for up to 1 year or as an adjunct to thiazide or beta-adrenoceptor blockers. "( The antihypertensive effects of doxazosin: a clinical overview.
Cox, DA; Leader, JP; Milson, JA; Singleton, W, 1986
)
2
"Doxazosin is a new quinazoline derivative that, like prazosin, has selectivity for alpha 1-receptors. "( Clinical pharmacology of doxazosin in patients with essential hypertension.
Caplan, N; Cubeddu, LX; Ferry, D; Fuenmayor, N, 1987
)
2.02
"Doxazosin is a potent, selective alpha 1-adrenoceptor antagonist which produces long-lasting antihypertensive effects in laboratory animals, with little effect on heart rate."( Doxazosin, a case history.
Campbell, SF; Davey, MJ, 1986
)
2.44

Effects

Doxazosin has a beneficial effect on some of the risk factors associated with coronary heart disease. It has a slower onset of action and longer plasma half-life than any other available selective alpha 1-adrenoceptor inhibitor.

Doxazosin has been shown to lower serum cholesterol levels in the cholesterol-fed (0.75% in a synthetic diet that contains sucrose and cholic acid) C57BR/cdJ mouse. It has a pharmacokinetic profile in both young adult and elderly subjects which is compatible with once-daily administration. Doxazasin treatment has been discouraged in hypertensive patients in order to prevent heart failure.

ExcerptReferenceRelevance
"Doxazosin has a direct renoprotective effect possibly by down-regulating SGLT2."( Doxazosin down-regulates sodium-glucose cotransporter-2 and exerts a renoprotective effect in rat models of acute renal injury.
Elshazly, SM; Nasr, AM; Rezq, S; Shaheen, A, 2020
)
2.72
"Doxazosin has a neutral effect on both peripheral and hepatic insulin action, but improves endothelium-dependent vasodilation."( Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action.
Atkinson, AB; Bassett, J; Bell, PM; Courtney, CH; Ennis, CN; McCance, DR; Sheridan, B, 2003
)
1.31
"Doxazosin mosylate has a lower complete volume expansion rate and side-effect rate as well for patients of pheochromocytoma. "( [Effects of doxazosin mosylate and phenoxybenzamine in preoperative volume expansion of pheochromocytoma: a comparative study in 38 cases].
Ji, ZG; Li, HZ; Pan, DL; Zeng, ZP, 2005
)
2.15
"Doxazosin has a slower onset of action and longer plasma half-life than any other available selective alpha 1-adrenoceptor inhibitor, which may confer advantages in terms of tolerability over the more rapidly absorbed and eliminated selective alpha 1-adrenoceptor inhibitors."( Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia.
Kirby, RS, 1994
)
1.4
"Doxazosin has a beneficial effect on some of the risk factors associated with coronary heart disease including elevated serum lipid levels, impaired glucose metabolism, insulin resistance and left ventricular hypertrophy."( Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.
Fulton, B; Sorkin, EM; Wagstaff, AJ, 1995
)
2.46
"Doxazosin has a longer terminal elimination half-life than prazosin."( Pharmacokinetic and pharmacodynamic studies with two alpha-adrenoceptor antagonists, doxazosin and prazosin in the rabbit.
Hamilton, CA; Reid, JL; Vincent, J, 1985
)
1.21
"Doxazosin has a pharmacokinetic profile in both young adult and elderly subjects which is compatible with once-daily administration."( The antihypertensive effects of doxazosin: a clinical overview.
Cox, DA; Leader, JP; Milson, JA; Singleton, W, 1986
)
1.28
"Doxazosin has a direct renoprotective effect possibly by down-regulating SGLT2."( Doxazosin down-regulates sodium-glucose cotransporter-2 and exerts a renoprotective effect in rat models of acute renal injury.
Elshazly, SM; Nasr, AM; Rezq, S; Shaheen, A, 2020
)
2.72
"Doxazosin has also demonstrated several modulator effects on renin-angiotensin system (RAS)- regulating aminopeptidase activities, which are highly involved in tumor growth in experimental glioma."( Differential Effects of Doxazosin on Renin-Angiotensin-System- Regulating Aminopeptidase Activities in Neuroblastoma and Glioma Tumoral Cells.
Martínez-Martos, JM; Ramírez-Expósito, MJ, 2019
)
1.54
"Doxazosin treatment has been discouraged in hypertensive patients in order to prevent heart failure (HF) development. "( Safety and efficacy of doxazosin as an "add-on" antihypertensive therapy in mild to moderate heart failure patients.
Arioli, F; Cuko, A; Fragasso, G; Gardini, C; Margonato, A; Palloshi, A; Roccaforte, R; Salerno, A; Spoladore, R, 2009
)
2.11
"Doxazosin has a neutral effect on both peripheral and hepatic insulin action, but improves endothelium-dependent vasodilation."( Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action.
Atkinson, AB; Bassett, J; Bell, PM; Courtney, CH; Ennis, CN; McCance, DR; Sheridan, B, 2003
)
1.31
"Doxazosin mosylate has a lower complete volume expansion rate and side-effect rate as well for patients of pheochromocytoma. "( [Effects of doxazosin mosylate and phenoxybenzamine in preoperative volume expansion of pheochromocytoma: a comparative study in 38 cases].
Ji, ZG; Li, HZ; Pan, DL; Zeng, ZP, 2005
)
2.15
"Doxazosin has a slower onset of action and longer plasma half-life than any other available selective alpha 1-adrenoceptor inhibitor, which may confer advantages in terms of tolerability over the more rapidly absorbed and eliminated selective alpha 1-adrenoceptor inhibitors."( Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia.
Kirby, RS, 1994
)
1.4
"Doxazosin has also been used successfully in combination with beta-adrenoceptor antagonists, diuretics, calcium channel antagonists, and angiotensin-converting enzyme inhibitors in patients with hypertension that is uncontrolled with monotherapy."( Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.
Fulton, B; Sorkin, EM; Wagstaff, AJ, 1995
)
2.46
"Doxazosin has the advantage of more convenient dosing (once daily) and unlike prazosin it does not produce orthostatic blood pressure falls; it is less toxic and better tolerated."( Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (Part One).
Dutkiewicz, S; Witeska, A, 1995
)
2.46
"Doxazosin has been shown to be effective in reducing the symptoms of BPH in elderly patients whose blood pressure is well controlled by concomitant antihypertensive medication."( Doxazosin in elderly patients with hypertension.
Fawzy, A; Weinberger, MH, 2000
)
2.47
"Doxazosin has blood-pressure-lowering effects comparable to those of other alpha 1-adrenoceptor inhibitors and to those of antihypertensives in other drug classes."( Doxazosin: a new alpha 1-adrenergic antagonist.
Babamoto, KS; Hirokawa, WT, 1992
)
2.45
"Doxazosin, which has beneficial effects on haemodynamic factors and lipid metabolism, may be a suitable agent for treating these patients."( [The effect of doxazosin on blood pressure, lipids, fibrinogen and plasminogen activator inhibitor. A comparative study among smokers and non-smokers with essential hypertension].
Brusletto, B; Daae, LN; Holme, I; Kierulf, P; Syvertsen, JO; Westheim, A, 1991
)
1.36
"Doxazosin, which has beneficial effects on haemodynamic factors and lipid metabolism, may be suitable for treating these patients."( Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects.
Brusletto, B; Daae, LN; Holme, I; Kierulf, P; Syvertsen, JO; Westheim, A, 1990
)
1.28
"Doxazosin has been shown to lower serum cholesterol levels in the cholesterol-fed (0.75% in a synthetic diet that contains sucrose and cholic acid) C57BR/cdJ mouse. "( Effects of doxazosin and other antihypertensives on serum lipid levels and lipoprotein lipase in the C57BR/cdJ mouse.
Hoover, KW; Krupp, MN; Valentine, JJ, 1989
)
2.11
"Doxazosin has a longer terminal elimination half-life than prazosin."( Pharmacokinetic and pharmacodynamic studies with two alpha-adrenoceptor antagonists, doxazosin and prazosin in the rabbit.
Hamilton, CA; Reid, JL; Vincent, J, 1985
)
1.21
"Doxazosin has a pharmacokinetic profile in both young adult and elderly subjects which is compatible with once-daily administration."( The antihypertensive effects of doxazosin: a clinical overview.
Cox, DA; Leader, JP; Milson, JA; Singleton, W, 1986
)
1.28

Actions

Doxazosin has a slower onset of action and longer plasma half-life than any other available selective alpha 1-adrenoceptor inhibitor. It can inhibit the growth of the prostate xenografts in the nude mice by inducing apoptosis.

ExcerptReferenceRelevance
"Doxazosin can inhibit the growth of the prostate xenografts in the nude mice by inducing apoptosis without affecting the cell proliferation. "( [Inhibitory effect of doxazosin on the growth of transplanted tumor of prostate cancer cell PC-3 in nude mice].
Dong, JQ; Guo, CY; Huang, XB; Liu, SJ; Wang, XF; Xu, KX; Xu, T; Ye, HY, 2005
)
2.09
"Doxazosin and Y-27632 generate effective CCSM relaxation in the presence of BOO."( Effect of doxazosin with and without rho-kinase inhibitor on human corpus cavernosum smooth muscle in the presence of bladder outlet obstruction.
Aslan, G; Demir, O; Esen, AA; Gidener, S; Murat, N, 2006
)
1.46
"Doxazosin has a slower onset of action and longer plasma half-life than any other available selective alpha 1-adrenoceptor inhibitor, which may confer advantages in terms of tolerability over the more rapidly absorbed and eliminated selective alpha 1-adrenoceptor inhibitors."( Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia.
Kirby, RS, 1994
)
1.4
"Doxazosin appears to inhibit the development of CHD on two fronts."( Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism.
Pool, JL, 1991
)
1.39

Treatment

Doxazosin treatment protected against the kidney damage and attenuated the associated biochemical changes. NB69 cells were more sensitive to the drug than U373-MG cells. Doxazasin treatment increased heparin-releasable lipoprotein lipase in fasted chow-fed mice.

ExcerptReferenceRelevance
"Doxazosin treatment protected against the kidney damage and attenuated the associated biochemical changes."( Doxazosin down-regulates sodium-glucose cotransporter-2 and exerts a renoprotective effect in rat models of acute renal injury.
Elshazly, SM; Nasr, AM; Rezq, S; Shaheen, A, 2020
)
2.72
"Doxazosin treatments promote a concentration-dependent inhibition on cell growth in both NB69 and U373-MG cells, being NB69 cells more sensitive to the drug than U373-MG cells. "( Differential Effects of Doxazosin on Renin-Angiotensin-System- Regulating Aminopeptidase Activities in Neuroblastoma and Glioma Tumoral Cells.
Martínez-Martos, JM; Ramírez-Expósito, MJ, 2019
)
2.26
"When doxazosin treatment was added, apoptotic indices increased in a dose-dependent manner (1, 10, and 25  μ M): nonsilencing 10, 27, and 52%; Hsp27-silencing: 14, 35, and 68%; c-FLIP silencing: 21, 46, and 78%; dual silencing: 38, 76, and 92%."( Dual silencing of Hsp27 and c-FLIP enhances doxazosin-induced apoptosis in PC-3 prostate cancer cells.
Cho, HJ; Cho, JM; Kang, JY; Kim, SS; Yang, HW; Yoo, TK, 2013
)
1.11
"Doxazosin XL treatment was associated with a nonsignificant treatment × time reduction in ratings on the CAPS hyperarousal subscale (P < .10) (but not on the CAPS Total score) and with significant treatment × time reductions in PCL-M ratings (P = .002)."( Doxazosin XL reduces symptoms of posttraumatic stress disorder in veterans with PTSD: a pilot clinical trial.
De La Garza, R; Haile, CN; Holst, M; Newton, TF; Raskind, MA; Rodgman, C; Thompson-Lake, D; Verrico, CD, 2016
)
3.32
"Doxazosin-treated prostate tissue showed decreased inflammatory reaction. "( Histologic influence of doxazosin and finasteride in benign prostatic hyperplasia accompanying chronic inflammation.
Park, DS; Shim, JY, 2008
)
2.1
"Doxazosin treatment has been discouraged in hypertensive patients in order to prevent heart failure (HF) development. "( Safety and efficacy of doxazosin as an "add-on" antihypertensive therapy in mild to moderate heart failure patients.
Arioli, F; Cuko, A; Fragasso, G; Gardini, C; Margonato, A; Palloshi, A; Roccaforte, R; Salerno, A; Spoladore, R, 2009
)
2.11
"Doxazosin GITS treatment resulted in optimal management of BP within the normal range, especially in pharmacologically or physiologically hypertensive patients."( Effects of α-blocker 'add on' treatment on blood pressure in symptomatic BPH with or without concomitant hypertension.
Chung, BH; Lee, SH; Mah, SY; Park, KK, 2010
)
1.08
"Doxazosin treatment significantly increased membrane-bound IRAP specific activity in rat prostate by 59.4%, whereas no changes were observed in the soluble fraction. "( Alpha-1-adrenergic receptor blockade modifies insulin-regulated aminopeptidase (IRAP) activity in rat prostate and modulates oxytocin functions.
Carrera-González, MP; de la Chica, S; Manuel Martínez-Martos, J; Mayas, MD; Ramírez-Expósito, MJ; Saníger, MA, 2011
)
1.81
"Doxazosin treatment was well tolerated and doxazosin alone produced minimal changes in heart rate and blood pressure. "( Noradrenergic α₁ receptor antagonist treatment attenuates positive subjective effects of cocaine in humans: a randomized trial.
Brown, G; De La Garza, R; Haile, CN; Kosten, TR; Mahoney, JJ; Newton, TF, 2012
)
1.82
"Doxazosin-treated prostates showed thickened bundles of collagen fibrils, activated fibroblasts, enlarged neurotransmitter vesicles and increased tissue immunostaining for collagen type I and type III when compared to untreated prostates. "( Fibrosis-related gene expression in the prostate is modulated by doxazosin treatment.
Almeida, FL; Delella, FK; Felisbino, SL; Lacorte, LM; Pai, MD, 2012
)
2.06
"Doxazosin treatment caused an up-regulation in the mRNA levels of alpha1A-AR in the rat bladder base and prostatic urethra, indicating that chronic doxazosin treatment may cause an alteration in the properties of alpha1A-AR subtype mRNA in these two areas."( Doxazosin-induced up-regulation of alpha 1A-adrenoceptor mRNA in the rat lower urinary tract.
Foster, HE; Latifpour, J; Pouresmail, M; Shin, D; Takahashi, W; Yono, M, 2004
)
2.49
"The doxazosin treatment did not further decrease the expression of an already low level of Bcl-2 in all prostate tumors, but it increased the expression of Bax, and the activation of caspase-3, and the cleavage of a downstream substrate, PARP."( Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis.
Chiang, CF; Son, EL; Wu, GJ, 2005
)
1.08
"Doxazosin treated rats had significantly heavier prostates compared to control rats."( Molecular classification of doxazosin-induced alterations in the rat prostate using gene expression profiling.
Foster, HE; Latifpour, J; Mane, S; Shin, D; Yono, M, 2005
)
1.34
"In doxazosin treated groups Smad-4 and IkappaB alpha expressions were higher than that of the control group."( [Inhibitory effect of doxazosin on the growth of transplanted tumor of prostate cancer cell PC-3 in nude mice].
Dong, JQ; Guo, CY; Huang, XB; Liu, SJ; Wang, XF; Xu, KX; Xu, T; Ye, HY, 2005
)
1.16
"Doxazosin treatment reduced blood pressure and normalized alterations in platelet function."( Effect of doxazosin gastrointestinal therapeutic system on platelet degranulation and platelet-leukocyte microaggregate formation induced by physiologic shear stress in hypertension.
Aznar, J; Gabriel, F; Guiral, V; Labiós, M; Martínez, M, 2006
)
1.46
"Doxazosin treatment proved to be safe and effective for distal-ureteral stones, as determined by earlier expulsion, decreased colic frequency, and absence of side effects. "( Doxazosin for the management of distal-ureteral stones.
Assimakopoulos, K; Athanasopoulos, A; Constantinides, C; Kallidonis, P; Katsakiori, PF; Liatsikos, EN; Perimenis, P; Stolzenburg, JU; Voudoukis, T, 2007
)
3.23
"Doxazosin treatment resulted in improvements in both urodynamic and symptomatic parameters associated with BPH."( Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups.
Chapple, CR; Janknegt, RA, 1993
)
1.27
"Doxazosin treatment produced a significant decrease in the daytime SBP and DBP but not in the nighttime BP values."( Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension.
Fujishima, M; Hirota, Y; Ito, Y; Takata, Y; Yoshizumi, T, 1995
)
1.28
"Both doxazosin treatment and good glycemic control normalized these abnormalities in diabetic rats."( Doxazosin prevents proteinuria and glomerular loss of heparan sulfate in diabetic rats.
Alluru, I; Jyothirmayi, GN; Reddi, AS, 1996
)
2.19
"Doxazosin treatment prevented the impairment in endothelium-dependent vascular relaxation in the high cholesterol/antioxidant-deficient group."( Effect of doxazosin on endothelial dysfunction in hypercholesterolemic/antioxidant-deficient rats.
Coffee, K; Guerra, J; Hayakawa, H; Raij, L, 1997
)
1.42
"Doxazosin treatment resulted in a dose-dependent reduction of basal insulin levels in group A to 16 +/- 3 microU/ml; p <0.05."( Effect of antihypertensive treatment with doxazosin on insulin sensitivity and fibrinolytic parameters.
Beckmann, R; Binder, BR; Christ, G; Gabriel, H; Huber, K; Mundigler, G; Zehetgruber, M, 1998
)
1.29
"Doxazosin (tonocardin) treatment was given for 11 weeks to 33 NIDDM patients with concomitant hypertension. "( [Antihypertensive therapy with doxazosin in patients with non-insulin-dependent diabetes mellitus].
Lazebnik, LB; Melichenko, SB; Serebrov, AN, 1998
)
2.03
"Doxazosin, an effective treatment for mild-to-moderate hypertension and benign prostatic hyperplasia, in its standard formulation requires a multiple-step titration regimen to minimize the potential for first-dose effects. "( Doxazosin GITS compared with doxazosin standard and placebo in patients with mild hypertension.
Os, I; Stokke, HP, 1999
)
3.19
"Doxazosin treatment reduced the formation of Bax-Bcl-2 complexes in the left ventricle of SHRs, and this was accompanied by a decrease in the levels of 85kDa PARP and a reduction in apoptotic left ventricular cells."( Doxazosin modifies Bcl-2 and Bax protein expression in the left ventricle of spontaneously hypertensive rats.
Aceituno, E; Ayala, R; Casado, S; Castilla, C; Farré, J; Fortes, J; García-Durán, M; González-Fernández, F; López-Farré, A; Rico, L; Rodríguez-Feo, JA, 2000
)
2.47
"Doxazosin treatment was well tolerated, with an adverse event profile similar to that of placebo."( The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study.
Black, HR; Garofalo, JL; Sollins, JS, 2000
)
1.37
"Doxazosin treatment prevented impaired vasodilatory response to SNP."( [Doxazosin and soluble guanylate cyclase in a rat model of hypertension].
Cabestrero, F; Casado, S; de Andrés, R; Farré, J; Fortes, J; Gómez, J; López-Farré, A; Núñez, A; Rico, L; Rodríguez-Feo, JA, 2001
)
1.94
"Doxazosin treatment improved the endothelial-independent relaxation and preserved the cGMP generating system in the vascular wall of SHRSP rats."( Reduction of the soluble cyclic GMP vasorelaxing system in the vascular wall of stroke-prone spontaneously hypertensive rats: effect of the alpha1 -receptor blocker doxazosin.
Casado, S; de Andrés, R; Fortes, J; García-Colis, E; Gomez, J; López-Blaya, A; López-Farré, A; Rico, L; Rodriguez-Feo, JA, 2002
)
1.23
"Doxazosin treatment partially prevented the accumulation of cholesterol and triglycerides in the liver."( Effects of the selective alpha 1-antagonist, doxazosin, on hepatic lipid levels and metabolism in the golden hamster.
Birkenhäger, JC; Jansen, H, 1991
)
1.26
"Doxazosin treatment (monotherapy in 76.2% of patients) significantly (p less than 0.05) reduced the blood pressure of patients in group 1 (-23/-17 mm Hg) after 10 weeks and maintained the control of blood pressure for patients in group 2."( Clinical experience with doxazosin in general medical practice in New Zealand.
Maslowski, AH, 1991
)
1.31
"With doxazosin treatment, the mean supine and standing SBPs were reduced by 15 mmHg and 13 mmHg, respectively."( An evaluation of the efficacy and safety of doxazosin in the treatment of hypertension associated with renal insufficiency.
Anderton, JL; Notghi, A, 1990
)
1
"Doxazosin treatment had no effect on either parameter of 125I-LDL binding."( Studies with doxazosin on the saturable binding of 125I-LDL by liver in normocholesterolemic mice.
Miller, NE; Nanjee, MN, 1987
)
1.36
"Doxazosin treatment increased heparin-releasable lipoprotein lipase in fasted chow-fed mice."( Effects of doxazosin and other antihypertensives on serum lipid levels and lipoprotein lipase in the C57BR/cdJ mouse.
Hoover, KW; Krupp, MN; Valentine, JJ, 1989
)
1.39
"Doxazosin treatment lowered serum triglycerides, whereas atenolol treatment produced an increase in serum triglycerides (p less than 0.001, week 30; p less than 0.01, week 50, between treatment groups)."( Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients.
Daae, L; Talseth, T; Vatle, S; Westlie, L, 1988
)
1.29
"Treatment with doxazosin or ramipril reduced aortic and brachial blood pressures (all P < 0.001), with greater reductions in aortic than brachial systolic blood pressures (P = 0.021) and aortic/brachial pulse pressure ratio (P = 0.005)."( The effects of alpha 1-adrenoceptor blockade and angiotensin converting enzyme inhibition on central and brachial blood pressure and vascular reactivity: the doxazosin-ramipril study.
Jekell, A; Kahan, T; Kalani, M, 2017
)
0.99
"Treatment with doxazosin also significantly increased OT concentration by 26.3%."( Alpha-1-adrenergic receptor blockade modifies insulin-regulated aminopeptidase (IRAP) activity in rat prostate and modulates oxytocin functions.
Carrera-González, MP; de la Chica, S; Manuel Martínez-Martos, J; Mayas, MD; Ramírez-Expósito, MJ; Saníger, MA, 2011
)
0.71
"Treatment with doxazosin triggered EphA2 receptor internalization, and suppressed haptotactic and chemotactic migration of prostate cancer, breast cancer, and glioma cells."( A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo.
Acharya, C; Ficker, E; Guo, H; Hsieh, JT; Lindner, DJ; Liu, L; MacKerell, AD; Miao, H; Myshkin, E; Page, P; Petty, A; Qin, H; Song, J; Tochtrop, GP; Wang, B, 2012
)
0.72
"Treatment with doxazosin positively influenced the metabolic profile."( [Hypertension and metabolic syndrome in population of one company. Monotherapy with amlodipine and doxazosin].
Ceremuzyński, L; Cybulski, J, 2002
)
0.87
"Treatment with doxazosin-GITS was significantly more effective than tamsulosin in relieving lower urinary tract symptoms."( A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia.
Kirby, RS, 2003
)
0.9
"Treatment with doxazosin GITS was well tolerated."( Effect of doxazosin GITS on 24-hour blood pressure profile in patients with stage 1 to stage 2 primary hypertension.
Lemmer, B; Nold, G, 2003
)
1.06
"Treatment with doxazosin increased blood flow to each tissue studied in SHRs."( Effects of doxazosin on blood flow and mRNA expression of nitric oxide synthase in the spontaneously hypertensive rat genitourinary tract.
Latifpour, J; Ueda, S; Yamamoto, Y; Yono, M; Yoshida, M, 2007
)
1.07
"Treatment with doxazosin (0.06 mg kg(-1) day(-1) for 14 days) did not alter systemic blood pressure but enhanced neo-angiogenesis in the ischaemic hindlimb, as measured by all our assays."( Endothelial alpha1-adrenoceptors regulate neo-angiogenesis.
Altobelli, GG; Campanile, A; Cervèro, P; Ciccarelli, M; Cimini, V; Galasso, G; Iaccarino, G; Pastore, L; Piscione, F; Santulli, G; Trimarco, B, 2008
)
0.69
"Treatment with doxazosin was effective and generally well tolerated."( Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men.
Kirby, RS, 1995
)
2.07
"Treatment with doxazosin is effective and well tolerated in the treatment of BPH. "( Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men.
Kirby, RS, 1995
)
2.09
"Treatment with doxazosin can lower blood pressure, reduce the levels of atherogenic lipids, increase the levels of cardioprotective lipids, reduce hyperinsulinaemia, insulin resistance and glucose intolerance, increase fibrinolysis, inhibit platelet aggregation, attenuate the adverse haemodynamic and haemostatic effects of smoking, and regress cardiac and smooth muscle hypertrophy."( Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient.
Pool, JL, 1994
)
1.02
"Treatment with doxazosin resulted in sustained benefits for BPH patients over the whole study period, with significant improvements in the severity (12.2%, P < 0.001) and bothersomeness (13.2%, P < 0.001) of BPH symptoms, and in the maximum urinary flow rate (26.6%, P < 0.05) from baseline to the end of the 4-year period. "( Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension.
Cook, E; Fawzy, A; Gonzalez, F; Hendry, A, 1999
)
0.91
"Treatment with doxazosin preserved the endothelium-independent relaxation response to sodium nitroprusside in aortic segments from SHRSP rats which was associated with an increased expression of the sGC beta1-subunit."( Reduction of the soluble cyclic GMP vasorelaxing system in the vascular wall of stroke-prone spontaneously hypertensive rats: effect of the alpha1 -receptor blocker doxazosin.
Casado, S; de Andrés, R; Fortes, J; García-Colis, E; Gomez, J; López-Blaya, A; López-Farré, A; Rico, L; Rodriguez-Feo, JA, 2002
)
0.85
"Treatment with doxazosin improved the severity category of hypertension for 88.4% of patients in group 1; 87.3% of patients were considered a therapy success."( Clinical experience with doxazosin in general medical practice in New Zealand.
Maslowski, AH, 1991
)
0.92
"Treatment with doxazosin produced a reduction in serum cholesterol (-3.1%) and triglyceride (-3.8%) levels, although these changes did not attain statistical significance."( A multicenter study of doxazosin in the treatment of essential hypertension in France.
Bonnet, G, 1991
)
0.93
"Treatment with doxazosin for eight weeks had no adverse effects on the effective renal plasma flow or glomerular filtration rate of these patients."( Effect of doxazosin on blood pressure and renal haemodynamics of hypertensive patients with renal failure.
Bailey, RR; Nairn, PL; Walker, RJ, 1986
)
1.01

Toxicity

Doxazosin was well tolerated with almost 90% of adverse experiences considered mild or moderate in severity. 10% of patients had withdrawn due to adverse events versus 4% with placebo (P < 0.01) Tamsulosin also well tolerated; only three patients (6%) in the tamsulOSin group reported an adverse event (dizziness)

ExcerptReferenceRelevance
" Adverse experiences were reported in 127 (44."( Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups.
Chapple, CR; Janknegt, RA, 1993
)
0.55
" Parameters evaluated included Boyarsky symptom score (Sx), peak uroflow (Qmax), blood pressure and occurrence of adverse events."( Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety.
Kaplan, SA; Olsson, CA; Soldo, KA, 1995
)
0.65
" Doxazosin was well tolerated with almost 90% of adverse experiences considered mild or moderate in severity."( Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group.
Dias, N; Fawzy, A; Gaffney, M; Ice, K; Kaplan, SA; Klimberg, I; Lepor, H; Mobley, DF, 1997
)
2.65
" Global assessment of adverse events was similar for both treatments (46."( [Randomized, comparative study to evaluate efficacy and safety of doxazosin versus nitrendipine in the treatment of mild to moderate hypertension].
Espejo Martínez, J; Sanz Guajardo, D, 1997
)
0.53
"Using claims data from a large Medigap plan, we examined the effect of initiating nonselective alpha1-antagonist therapy on the incidence of hypotension-related adverse events likely to be associated with vascular alpha-adrenoreceptor antagonism in patients with BPH."( Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study.
Chao, J; Chrischilles, E; Gilden, D; Kreder, KJ; Rubenstein, L; Shah, H, 2001
)
0.31
" We examined the rate of possible hypotension-related adverse events (diagnosis codes for hypotension, syncope, dizziness, fractures, and other injuries) per 10,000 person-days for men who began therapy with alpha1 antagonists and for a random sample of nonusers, stratified by prior use of other antihypertensive agents."( Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study.
Chao, J; Chrischilles, E; Gilden, D; Kreder, KJ; Rubenstein, L; Shah, H, 2001
)
0.31
"Despite adverse side effects, phenoxybenzamine has been widely used for the preoperative management of patients with pheochromocytoma."( Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma.
Farndon, JR; Prys-Roberts, C, 2002
)
0.63
" A total of 154 patients suffered adverse events (AE), 127 during phase I and 27 in phase II."( Safety and effectiveness of replacing standard doxazosin with doxazosin in the gastrointestinal therapeutic system (GITS) formulation in elderly hypertensive patients.
Anegón, M; Apaolaza, I; Carrasco, P; Esteban, J; Gil, A; Jiménez-García, R, 2003
)
0.58
" Laboratory tests were performed, adverse events recorded, and prostatic symptomatology examined."( Efficacy and safety of doxazosin GITS in hypertensive renal transplant patients: comparison of 8 and 4 mg.
Hurtado, S; Lloveras, J; Oliveras, A; Puig, JM; Vázquez, S, 2003
)
0.63
" Palpitations were the only reported adverse event after treatment (incidence similar to placebo)."( Efficacy and safety of doxazosin GITS in hypertensive renal transplant patients: comparison of 8 and 4 mg.
Hurtado, S; Lloveras, J; Oliveras, A; Puig, JM; Vázquez, S, 2003
)
0.63
" Doxazosin proved to have a good tolerance and safe profile."( Efficacy and safety of doxazosin GITS in hypertensive renal transplant patients: comparison of 8 and 4 mg.
Hurtado, S; Lloveras, J; Oliveras, A; Puig, JM; Vázquez, S, 2003
)
1.54
"To evaluate the efficacy and adverse effects of doxazosin for treating lower urinary tract symptoms (LUTS) compatible with benign prostatic obstruction (BPO)."( Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects.
Howe, RW; MacDonald, R; Wilt, TJ, 2004
)
2.02
" Adverse events reported for combined therapy were similar to those with each monotherapy."( Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects.
Howe, RW; MacDonald, R; Wilt, TJ, 2004
)
1.77
" Adverse events (AEs) and blood pressure (BP) were also recorded."( Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.
Chung, BH; Hong, SJ, 2006
)
0.57
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" The primary parameters used for safety evaluation were vital signs (blood pressure and heart rate) and adverse events."( Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Birowo, P; Djati, W; Rahardjo, D; Soebadi, DM; Sugandi, S; Wahyudi, I, 2006
)
0.58
" Tamsulosin was well tolerated; only three patients (6%) in the tamsulosin group reported an adverse event (dizziness) while 11 patients (22%) in the doxazosin group reported an adverse event (dizziness), one of whom withdrew from the study."( Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Birowo, P; Djati, W; Rahardjo, D; Soebadi, DM; Sugandi, S; Wahyudi, I, 2006
)
0.78
" Prazosin prevented hepatotoxicity when administered 1 h before a toxic paracetamol insult and importantly, when administered up to 1 h post paracetamol injection."( alpha(1)-Adrenoceptor antagonists prevent paracetamol-induced hepatotoxicity in mice.
Kitteringham, NR; Macdonald, I; Park, BK; Randle, LE; Sathish, JG; Williams, DP, 2008
)
0.35
" Adverse events related to doxazosin treatment were rare and led to discontinuation of the therapy in only five patients (5."( Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension.
Ceral, J; Solar, M, 2009
)
2.09
"Doxazosin, "on top" of other antihypertensive treatments was safe and effective, and did not appear to be associated with HF-related hospitalization and mortality rates in our patients with mild/moderate HF."( Safety and efficacy of doxazosin as an "add-on" antihypertensive therapy in mild to moderate heart failure patients.
Arioli, F; Cuko, A; Fragasso, G; Gardini, C; Margonato, A; Palloshi, A; Roccaforte, R; Salerno, A; Spoladore, R, 2009
)
2.11
" The most common treatment-related adverse event was dizziness."( Efficacy and safety of the doxazosin gastrointestinal therapeutic system for the treatment of benign prostate hyperplasia.
Chang, CH; Cheng, CL; Schou, M; Sun, GH; Tsui, KH; Wu, TT, 2010
)
0.66
" Doxazosin was safe and well tolerated."( Long-term safety, tolerability, and efficacy of α1-adrenergic blocker in young men with primary bladder neck obstruction: results from a single centre in China.
Dong, C; Gao, W; Han, X; Jia, R; Li, B; Li, S; Xiao, C, 2012
)
1.29
"As a surgical treatment of pheochromocytomas, laparoscopic adrenalectomy is an effective and safe approach, in selected cases even for PCCs >6 cm in diameter, although patients with such large tumors may have a higher conversion rate and more intraoperative hypertensive crises."( Laparoscopic adrenalectomy, a safe procedure for pheochromocytoma. A retrospective review of clinical series.
Colantuoni, V; Conzo, G; Corcione, F; De Palma, M; Ferraro, F; Milone, M; Musella, M; Napolitano, S; Palazzo, A; Pasquali, D; Santini, L; Sinisi, AA, 2013
)
0.39
" α(1) Blockers generally lead to more adverse effects compared with placebo, and those caused by terazosin were more frequent than others."( The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews.
Liu, Y; Mao, C; Qin, X; Yang, K; Yang, Z; Yuan, J, 2013
)
0.39
" The adverse effects caused by α(1) blockers are generally mild and well-tolerated."( The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews.
Liu, Y; Mao, C; Qin, X; Yang, K; Yang, Z; Yuan, J, 2013
)
0.39
"The article presents a method of conservative treatment of men with I-II stage prostatic adenoma using a combination of doxazosin and indigal, which has antioxidant, antiproliferative and anti-inflammatory properties, that allowed improving urodynamic parameters and reducing the progression prostate adenoma, minimizing the adverse effects of treatment."( [Results of open multicenter study of the safety of doxazosin in combination with indigal in men with stages I-II prostatic adenoma].
Abzalilov, RA; Bliumberg, BI; Boiarko, AV; Grigor'ev, MÉ; Izmaĭlov, AA; Kazikhinoruv, AA; Komiakov, BK; Pavlov, VN; Sivkov, AV,
)
0.59
" This includes less toxic drugs, more selective towards tumor cells, causing less damage to the patient."( Phosphatidylinositol 3-Kinase/AKT Pathway Inhibition by Doxazosin Promotes Glioblastoma Cells Death, Upregulation of p53 and Triggers Low Neurotoxicity.
Battastini, AM; Coelho, BP; de Quadros, AH; Gaelzer, MM; Gonçalves, CA; Guerra, MC; Guma, FC; Hoppe, JB; Salbego, CG; Setton-Avruj, P; Terra, SR; Usach, V, 2016
)
0.68
" The outcome measures were stone expulsive rate (SER), stone expulsive time (SET), pain episodes, analgesics consumption, and adverse events."( Efficacy and Safety of Doxazosin in Medical Expulsive Therapy for Distal Ureteral Stones: A Systematic Review and Meta-analysis.
Ma, L; Wang, F; Yang, L; Zou, S, 2020
)
0.87
" 9 in 286 participants reported doxazosin-related adverse events; most were mild to moderate."( Efficacy and Safety of Doxazosin in Medical Expulsive Therapy for Distal Ureteral Stones: A Systematic Review and Meta-analysis.
Ma, L; Wang, F; Yang, L; Zou, S, 2020
)
1.15
"This meta-analysis may suggest that doxazosin is a safe and effective MET for distal ureteral stones less than 10mm."( Efficacy and Safety of Doxazosin in Medical Expulsive Therapy for Distal Ureteral Stones: A Systematic Review and Meta-analysis.
Ma, L; Wang, F; Yang, L; Zou, S, 2020
)
1.14
" Although doxazosin resulted in significantly more adverse effects compared with the placebo, the patient's symptoms were mild and no further medical interventions were required."( The safety and efficacy of doxazosin in medical expulsion therapy for distal ureteric calculi: A meta-analysis.
Cao, H; Cao, P; Gao, Z; Sun, Z; Wang, W; Yu, B; Zhang, F; Zhang, J; Zheng, X, 2021
)
1.32
"To describe the otorhinolaryngological adverse effects of the main drugs used in urological practice."( Otorhinolaryngological adverse effects of urological drugs.
Ganança, FF; Lopes, KC; Maia, NPD,
)
0.13
"A review of the scientific literature was performed using a combination of specific descriptors (side effect, adverse effect, scopolamine, sildenafil, tadalafil, vardenafil, oxybutynin, tolterodine, spironolactone, furosemide, hydrochlorothiazide, doxazosin, alfuzosin, terazosin, prazosin, tamsulosin, desmopressin) contained in publications until April 2020."( Otorhinolaryngological adverse effects of urological drugs.
Ganança, FF; Lopes, KC; Maia, NPD,
)
0.31
"The main drugs used in Urology may cause several otorhinolaryngological adverse effects."( Otorhinolaryngological adverse effects of urological drugs.
Ganança, FF; Lopes, KC; Maia, NPD,
)
0.13
"Most of the drugs used in urological practice have otorhinolaryngological adverse effects."( Otorhinolaryngological adverse effects of urological drugs.
Ganança, FF; Lopes, KC; Maia, NPD,
)
0.13
" Frailty may contribute to both symptom progression and serious adverse events (SAEs), shifting the balance of benefits and harms of drug therapy."( Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy.
Bauer, SR; Covinsky, K; Ensrud, KE; Liu, TT; McVary, KT; Newman, JC; Ricke, WA; Suskind, AM; Walter, LC, 2021
)
0.62
" This systematic review aims at presenting a complete overview of evidence over the benefits and risks of alpha-1 antagonist treatment in people ≥ 65 years, and at deriving recommendations for a safe application of alpha-1 antagonists in older adults from the evidence found."( Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing.
Kienberger, G; Mann, E; Mansbart, F; Sönnichsen, A, 2022
)
0.72
" Analyses of the risk profile indicated an increase in vasodilation related adverse events and sexual adverse events for some agents."( Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing.
Kienberger, G; Mann, E; Mansbart, F; Sönnichsen, A, 2022
)
0.72
"Patients on alpha-blockers (ABs) treatment may have an increased risk of adverse events (AEs)."( Adverse events related to alpha-blockers: analysis of real-life data from Eudra-Vigilance.
Baldassarri, V; Cicione, A; D'Annunzio, S; DE Nunzio, C; Franco, A; Guarnotta, G; Lombardo, R; Mancini, E; Nacchia, A; Rovesti, LM; Tema, G; Tubaro, A; Voglino, OA, 2023
)
0.91
"Eudra-Vigilance (EV) database is the system for managing and analyzing information on suspected adverse reactions to medicines which have been authorized or being studied in clinical trials in the European Economic Area (EEA)."( Adverse events related to alpha-blockers: analysis of real-life data from Eudra-Vigilance.
Baldassarri, V; Cicione, A; D'Annunzio, S; DE Nunzio, C; Franco, A; Guarnotta, G; Lombardo, R; Mancini, E; Nacchia, A; Rovesti, LM; Tema, G; Tubaro, A; Voglino, OA, 2023
)
0.91

Pharmacokinetics

Doxazosin has a longer terminal elimination half-life than prazosin. The aim of this study was to assess the potential pharmacokinetic interaction when coadministered with finasteride. There was no significant relationship between plasma eliminationhalf-life or the AUC for doxazos in and the degree of renal impairment.

ExcerptReferenceRelevance
" There was no significant relationship between plasma elimination half-life or the AUC for doxazosin and the degree of renal impairment."( The pharmacokinetics of doxazosin in patients with hypertension and renal impairment.
Dewhurst, AG; Honeywell, R; Oliver, RM; Renwick, AG; Upward, JW; Waller, DG, 1990
)
0.81
" The pharmacokinetic parameters of doxazosin in both single- and consecutive-dose study were 18."( Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension.
Kaneko, Y; Miyajima, E; Miyakawa, T; Shionoiri, H; Takagi, N; Umemura, S; Yasuda, G; Yoshimura, H, 1987
)
0.77
" However, recent studies have shown that it has substantial antihypertensive efficacy with minimal side effects at low doses, and that half-life is long enough to allow twice daily administration."( Comparison of pharmacokinetics and pharmacodynamics of adrenoceptor agonists and antagonists as antihypertensive agents.
Anavekar, SN; Conway, EL; Drummer, OH; Howes, LG; Jarrott, B; Louis, WJ; McNeil, JJ; Workman, B, 1987
)
0.27
" The elimination half-life in plasma was 10."( Single-dose and steady-state pharmacokinetics of doxazosin given in combination with chlorothiazide to hypertensive subjects.
Conway, EL; Drummer, OH; Howes, LG; Louis, WJ; McNeil, JJ; Meng, L; Raymond, K, 1989
)
0.53
" Doxazosin has a longer terminal elimination half-life than prazosin."( Pharmacokinetic and pharmacodynamic studies with two alpha-adrenoceptor antagonists, doxazosin and prazosin in the rabbit.
Hamilton, CA; Reid, JL; Vincent, J, 1985
)
1.4
" For single doses, oral bioavailability has been calculated to be about 65%; terminal elimination half-life is approximately 10 to 12 hours."( Pharmacokinetic overview of doxazosin.
Elliott, HL; Meredith, PA; Reid, JL, 1987
)
0.57
" The pharmacokinetic and pharmacodynamic profiles of intravenous and oral doxazosin were investigated in 6 normotensive volunteers."( Pharmacokinetic and pharmacodynamic modelling of the alpha adrenoceptor antagonist doxazosin.
Elliott, HL; Kelman, AW; Meredith, PA; Reid, JL; Vincent, J, 1988
)
0.73
" Mean plasma concentrations of doxazosin were proportional to dose and the plasma half-life was 11."( The pharmacokinetics and pharmacodynamics of doxazosin compared with atenolol during long-term double-blind treatment.
Faulkner, JK; Himanen, P; Karjalainen, U; Saraste, M, 1987
)
0.82
" The plasma elimination half-life during the dose interval in these patients was 16."( A double-blind and cross-over comparison of once daily doxazosin and placebo with steady-state pharmacokinetics in elderly hypertensive patients.
Hosie, J; Scott, MG; Scott, PJ, 1988
)
0.52
" Since the peak treatment effect was later than predicted from previous pharmacokinetic studies, it is suggested that the timing of the peak effect may depend on the prevailing level of alpha-adrenergic tone, as well as on the pharmacokinetics of the drug."( Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Results of the HALT Study. Hypertension and Lipid Trial Study Group.
Levenstein, M; Pickering, TG; Walmsley, P, 1994
)
0.61
" Pharmacokinetic data were evaluated from blood samples serially collected for 72 hours after drug administration on the last day of each phase."( Effect of time of administration on the pharmacokinetics and tolerance of doxazosin in healthy male volunteers.
Chung, M; Dias, N; Phillips, K; Vashi, V, 1996
)
0.52
" The aim of this study was to assess the potential pharmacokinetic interaction of doxazosin or terazosin when coadministered with finasteride."( Pharmacokinetic interaction between finasteride and terazosin, but not finasteride and doxazosin.
Chung, M; Hilbert, J; Lawrence, V; Phillips, K; Vashi, V, 1998
)
0.75
"A controlled-release gastrointestinal therapeutic system (GITS) formulation of doxazosin mesylate, a long-acting selective alpha1-adrenoceptor antagonist, was developed to enhance the pharmacokinetic profile and simplify the titration schedule by precisely controlling drug delivery rate, permitting an initial dose of 4 mg once daily, compared with standard doxazosin, which is initiated at 1 mg day-1 and titrated to a higher therapeutically effective dose."( Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation.
Chung, M; Meredith, P; Puente, J; Sweeney, M; Vashi, V, 1999
)
0.82
"The GITS formulation of doxazosin enhances the pharmacokinetic profile compared with doxazosin standard, allowing more gradual absorption of doxazosin, and a reduced plasma doxazosin peak-to-trough concentration ratio."( Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation.
Chung, M; Meredith, P; Puente, J; Sweeney, M; Vashi, V, 1999
)
0.9
" The assay has been successfully applied to plasma sample ana-lysis for pharmacokinetic study."( Validation and pharmacokinetic application of a method for determination of doxazosin in human plasma by high-performance liquid chromatography.
Nermhom, P; Saraphanchotiwitthaya, A; Sripalakit, P, 2006
)
0.56
" This method was used successfully for a pharmacokinetic study in plasma after oral administration of multiple 4-mg dose of doxazosin gastrointestinal therapeutic system formulation to 16 healthy volunteers."( Pharmacokinetics of doxazosin gastrointestinal therapeutic system after multiple administration in Korean healthy volunteers.
Chun, IK; Gwak, HS; Kwon, YH; Yoon, SJ, 2007
)
0.87
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"In this study, the stereoselective pharmacokinetics of doxazosin enantiomers and their pharmacokinetic interaction were studied in rats."( Enantioselective pharmacokinetics of doxazosin and pharmacokinetic interaction between the isomers in rats.
Du, Q; Kong, D; Li, Q; Li, T; Ren, L; Zhao, J; Zhen, Y, 2015
)
0.94

Compound-Compound Interactions

Doxazosin (mean dose 11 mg) given once daily in combination with 100 mg atenolol (n = 44) was compared with placebo and atenlol ( n = 43) i

ExcerptReferenceRelevance
"Doxazosin (mean dose 11 mg) given once daily in combination with 100 mg atenolol (n = 44) was compared with placebo and atenolol (n = 43) in a double-blind, multicenter study in patients with mild to moderate essential hypertension."( Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial.
Christensen, CC; Dathan, R; Dean, S; Searle, M; Westheim, A, 1990
)
3.16
"To assess the renal benefits of combined angiotensin-converting enzyme inhibition and alpha(1)-adrenergic antagonism, we studied the antihypertensive and renoprotective effects of temocapril (TMP) alone and in combination with doxazosin (DOX) in spontaneously hypertensive rats (SHR)/Izumo rats with renal ablation."( Renoprotective effect of angiotensin-converting enzyme inhibitor combined with alpha1-adrenergic antagonist in spontaneously hypertensive rats with renal ablation.
Abe, K; Ito, O; Kanazawa, M; Kohzuki, M; Kurosawa, H; Minami, N; Saito, T; Yasujima, M, 2004
)
0.51
" The former was treated by applying the CRS-2280E extraorgan short-wave capacitance field hyperthermia system to the prostate once an hour every other day for 7 times, combined with anal administration of 1 Qianliean suppository and oral doxazosin 4 mg before bedtime every night for 2 weeks, while the latter underwent simple local hyperthermia."( [Medication combined with local hyperthermia: a desirable therapy for chronic prostatitis pain symptoms].
Sun, FL; Zang, T; Zhang, Y, 2008
)
0.53
"To study the clinical effects of kidney-tonifying and dampness-expelling Chinese herbal medicine combined with doxazosin in the treatment of chronic epididymitis."( [Kidney-tonifying and dampness-expelling Chinese herbal medicine combined with doxazosin for the treatment of chronic epididymitis].
Jin, BF; Xia, GS; Xue, YY; Zhang, XD; Zheng, LW; Zhou, YC, 2010
)
0.8
"A total of 64 patients with chronic epididymitis were equally randomized into a treatment and a control group, the former treated with kidney-tonifying and dampness-expelling Chinese herbal decoction combined with doxazosin, and the latter given doxazosin only, both for 4 weeks."( [Kidney-tonifying and dampness-expelling Chinese herbal medicine combined with doxazosin for the treatment of chronic epididymitis].
Jin, BF; Xia, GS; Xue, YY; Zhang, XD; Zheng, LW; Zhou, YC, 2010
)
0.77
"Either doxazosin alone or kidney-tonifying and dampness-expelling Chinese herbal decoction combined with doxazosin is obviously effective on chronic epididymitis, but the combined medication produces an even better efficacy."( [Kidney-tonifying and dampness-expelling Chinese herbal medicine combined with doxazosin for the treatment of chronic epididymitis].
Jin, BF; Xia, GS; Xue, YY; Zhang, XD; Zheng, LW; Zhou, YC, 2010
)
1.04
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
"To assess the clinical effect and safety of the Chinese medicine Longbishu Capsule combined with mesylate doxazosin in the treatment of benign prostatic hyperplasia (BPH) of the kidney deficiency and blood stagnation type."( [Longbishu Capsule combined with mesylate doxazosin: an efficacious therapy for benign prostatic hyperplasia].
Bi, MS; Chang, DG; Chen, DA; Li, GS; Peng, CH; Yang, XZ; You, YD; Yu, XJ; Zhang, PH, 2015
)
0.89
" Alpha blockers in combination with muscarinic receptor antagonists may have the potential to improve symptoms."( A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia.
Cao, Y; Chen, T; Guo, L; Niu, H; Wang, Y; Yang, X, 2016
)
0.65

Bioavailability

Doxazosin GITS relative bioavailability is approximately 60%. The aim of the present work was to evaluate the pharmacokinetics and bioavailability of doxazos in GITS.

ExcerptReferenceRelevance
" Significant accumulation of doxazosin occurred with chronic dosing, but comparison of dose-adjusted AUC after single and chronic dosing suggested that there was no change in clearance or bioavailability during chronic administration."( The pharmacokinetics of doxazosin in patients with hypertension and renal impairment.
Dewhurst, AG; Honeywell, R; Oliver, RM; Renwick, AG; Upward, JW; Waller, DG, 1990
)
0.88
" It is readily absorbed, with high bioavailability and a relatively long plasma half-life, neither of which property is influenced by age."( Clinical pharmacotherapeutics of doxazosin.
Taylor, SH, 1989
)
0.56
" For single doses, oral bioavailability has been calculated to be about 65%; terminal elimination half-life is approximately 10 to 12 hours."( Pharmacokinetic overview of doxazosin.
Elliott, HL; Meredith, PA; Reid, JL, 1987
)
0.57
" The volume of distribution increased significantly with age although the bioavailability and clearance were not significantly different in the two groups."( The pharmacokinetics of doxazosin in elderly normotensives.
Elliott, HL; Meredith, PA; Reid, JL; Vincent, J, 1986
)
0.58
" The aim of the present work was to evaluate the pharmacokinetics and bioavailability of doxazosin GITS with respect to the effect of food, age and gender, and multiple dosing."( Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation.
Chung, M; Meredith, P; Puente, J; Sweeney, M; Vashi, V, 1999
)
0.82
"A three-way crossover study in 24 subjects assessed the comparative bioavailability of doxazosin GITS under fed and fasting conditions and doxazosin standard under fasting condition."( Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation.
Chung, M; Meredith, P; Puente, J; Sweeney, M; Vashi, V, 1999
)
0.82
" The relative bioavailability of doxazosin GITS is approximately 60%."( Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation.
Chung, M; Meredith, P; Puente, J; Sweeney, M; Vashi, V, 1999
)
0.88
" Alf was not due to the species difference in its bioavailability and biotransformation."( Selective effects of alfuzosin and doxazosin with intraduodenal administration on urethral pressure of cats.
Fu, SX; Li, YS; Ren, LM; Wu, ZJ; Yang, ZH, 1999
)
0.58
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
"This study aims to develop a standard protocol for the relative bioavailability testing of doxazosin mesylate tablets."( LC-MS determination and relative bioavailability of doxazosin mesylate tablets in healthy Chinese male volunteers.
Chen, B; Li, H; Liu, W; Liu, X; Ma, N; Wang, F; Xiang, D; Zhang, B; Zhu, Y, 2007
)
0.81
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
"05) in terms of in vitro release and bioavailability in comparison to plain HEC matrices."( Pulse release of doxazosin from hydroxyethylcellulose compression coated tablet: mechanistic and in vivo study.
Biswas, N; Guha, A; Kuotsu, K; Sahoo, RK, 2015
)
0.76
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Doxazosin has the advantage of more convenient dosing (once daily) and unlik. Patients with BPH who are already being treated for hypertension with doxazos in need no alteration in their dosage regimen. Doxazasin can be used as a single agent to treat both conditions.

ExcerptRelevanceReference
"In previously untreated rats, pretreatment with enalaprilat shifted the dose-response curve for the hypotensive effect of doxazosin to the left, indicating synergism."( A study of the interaction between the hypotensive actions of doxazosin and enalaprilat in anaesthetized rats.
Marwood, JF; Stokes, GS; Tierney, G, 1992
)
0.73
" Orthostatic hypotension after the first dose occurs infrequently and may be minimized by initiating therapy at a dosage of 1 mg/day."( Doxazosin: a new alpha 1-adrenergic antagonist.
Babamoto, KS; Hirokawa, WT, 1992
)
1.73
" Therefore, after 4 weeks of washout with placebo (phase 1), doxazosin (dosage range from 1 to 16 mg, plus hydrochlorothiazide when necessary) was given to 11 essential hypertensive patients (6 M, 5 F, age range 34-63 years) for 8 weeks (phase 2) in order to achieve diastolic blood pressure values less than 90 mmHg; this dosage was then maintained for a further 20 weeks up to the end of the study (phase 3)."( Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin.
Agabiti-Rosei, E; Beschi, M; Calebich, S; Castellano, M; Muiesan, G; Muiesan, ML; Rizzoni, D; Zulli, R, 1992
)
0.75
" The dose was titrated individually upwards from 1 mg until the diastolic blood pressure was below 90 mm Hg, side-effects precluded further dosage increase or the maximum daily dose of 16 mg was achieved."( Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients.
Huupponen, R; Lehtonen, A; Vähätalo, M, 1992
)
0.69
" Doxazosin produced rightward shifts of the PE pressor dose-response curves but had no effect on responses to AII."( Vascular pressor responses in treated and untreated essential hypertension.
Donnelly, R; Elliott, HL; Howie, CA; Reid, JL; Sumner, DJ, 1990
)
1.19
" The pharmacokinetics of doxazosin, following a single oral dose (1 mg) and chronic oral dosing (doubling doses up to a maximum of 16 mg day-1), were studied in 18 patients with mild to moderate hypertension and stable renal function varying from normal to severely impaired."( The pharmacokinetics of doxazosin in patients with hypertension and renal impairment.
Dewhurst, AG; Honeywell, R; Oliver, RM; Renwick, AG; Upward, JW; Waller, DG, 1990
)
0.89
" Overall, side effects were minimal and did not necessitate reducing the dosage or discontinuing active therapy."( An evaluation of the efficacy and safety of doxazosin in the treatment of hypertension associated with renal insufficiency.
Anderton, JL; Notghi, A, 1990
)
0.54
") for evaluation of its consecutive dosing effect."( Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension.
Kaneko, Y; Miyajima, E; Miyakawa, T; Shionoiri, H; Takagi, N; Umemura, S; Yasuda, G; Yoshimura, H, 1987
)
0.49
" Starting at one mg, dosage was doubled every 2 weeks during a 10-week treatment period to a maximum dose of 16 mg once daily."( Alpha-1 adrenoceptor blockade with doxazosin in hypertension: effects on blood pressure and lipoproteins.
Ames, RP; Kiyasu, JY, 1989
)
0.55
" A U-shaped dose-response curve to compounds with mixed alpha 2- and alpha 1-antagonist properties may be constructed, which emphasizes the importance of the dose-dependent selectivity of these antagonists at alpha 2- and alpha 1-receptors."( Human vascular smooth muscle responses mediated by alpha 2 mechanisms in vivo and in vitro.
Calvete, J; Hayes, R; Martin, G; Sever, P; Thom, S, 1985
)
0.27
"The effect of nifedipine on pressor dose-response curves to phenylephrine, alpha-methylnoradrenaline and angiotensin II was determined in anaesthetized cats pretreated with propranolol and atropine."( Lack of differential inhibition by nifedipine of pressor responses induced by alpha 1- and alpha 2-adrenoceptor agonists and by angiotensin II in anaesthetized cats.
Alabaster, VA; Solca, AM, 1985
)
0.27
" Pressor response studies in the young subjects confirmed the alpha 1-adrenoceptor antagonist activity of doxazosin with significant rightward shifts of the dose-response curves for the selective alpha 1-adrenoceptor agonist phenylephrine."( Clinical pharmacological studies with doxazosin.
Elliott, HL; Meredith, PA; Reid, JL; Vincent, J, 1986
)
0.76
" Prazosin causes a dose-related decrease in blood pressure in humans; twice-daily dosing is sufficient for 24-hour blood pressure control."( Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists.
Reid, JL; Vincent, J, 1986
)
0.27
" Patients were then maintained for another 4 weeks on the dosage necessary to control diastolic BP to less than or equal to 90 mm Hg (phase 3)."( A multicenter trial of doxazosin in West Germany.
Rosenthal, J, 1987
)
0.58
" During long-term treatment, no significant changes in the disposition of doxazosin have been reported; with dosages up to the maximum clinically used dosage of 16 mg daily, there is no evidence of dose-dependent pharmacokinetics."( Pharmacokinetic overview of doxazosin.
Elliott, HL; Meredith, PA; Reid, JL, 1987
)
0.8
" Doxazosin significantly lowers both standing and supine blood pressure and appears to maintain this antihypertensive effect over a 24-hour dosing interval."( Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.
Brogden, RN; Young, RA, 1988
)
2.63
" In controlled double-blind studies involving approximately 550 patients on doxazosin 1-16 mg once daily, significant reductions in both standing and supine BP were maintained throughout the 24 h dosing interval."( The antihypertensive effects of doxazosin: a clinical overview.
Cox, DA; Leader, JP; Milson, JA; Singleton, W, 1986
)
0.78
" There was no evidence of a dose-response relationship for DOX; however, DOX serum levels were linearly related to the dose."( Effect of doxazosin monotherapy on blood pressure and plasma lipids in patients with essential hypertension.
Bloomfield, R; Cubeddu, LX; Halperin, A; Klotman, PE; Nelson, EB; Pickering, BI; Pool, JL; Wombolt, DG, 1988
)
0.68
"The antihypertensive effects and steady-state pharmacokinetics of doxazosin, as well as the bioequivalence of four dosage forms, were studied in 25 hypertensive patients."( Doxazosin in patients with hypertension.
Conrad, KA; Fagan, TC; Falkner, FC; Lazar, JD; Lee, S; Mackie, MJ; Mayshar, PV; Souhrada, JF, 1988
)
1.95
"alpha-Adrenoceptor antagonists have been compared for their effects on dose-response curves of fast and slow components of contraction of the rat aorta to noradrenaline (NA)."( Non-competitive antagonism of the alpha-adrenoceptor-mediated fast component of contraction of rat aorta, by doxazosin and prazosin.
Downing, OA; Wilson, KA; Wilson, VG, 1983
)
0.48
"(1) When incremental infusions of drugs that increase blood pressure are given to human subjects to assess "pressor responsiveness," only the lower part of the sigmoid dose-response curve can be obtained."( Analysis of the pressor dose response.
Elliott, HL; Reid, JL; Sumner, DJ, 1982
)
0.26
"In this pilot study, the effect of dosing schedule on the efficacy and safety of the long-acting alpha 1-adrenergic blocker doxazosin (DOX) was evaluated in 48 consecutive, normotensive men (mean age, 61."( Effect of dosing regimen on efficacy and safety of doxazosin in normotensive men with symptomatic prostatism: a pilot study.
Kaplan, SA; Olsson, CA; Soldo, KA, 1994
)
0.75
"These data suggest that evening dosing does not diminish efficacy yet may enhance toleration of DOX."( Effect of dosing regimen on efficacy and safety of doxazosin in normotensive men with symptomatic prostatism: a pilot study.
Kaplan, SA; Olsson, CA; Soldo, KA, 1994
)
0.54
" At the end of each dosage cycle the following investigations were performed: a) peak urinary flow, b) residual urinary volume, c) funneling of the prostatic urethra by means of permictional transrectal echography, d) Boyarsky's score."( [Single-blind study of the effect of doxazosin mesylate in benign prostatic hypertrophy].
Belgrano, E; Deriu, M; Paoni, A; Siracusano, S; Tomasi, PA; Trombetta, C, 1994
)
0.56
"A total of 248 hypertensive patients 45 years old or older with benign prostatic hyperplasia (BPH) was included in this 16-week, multicenter, double-blind, placebo-controlled, parallel-group dose-response study."( Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study.
Chrysant, SG; Conn, RL; Dias, N; Gaffney, M; Gillenwater, JY; Ice, K; Roy, J, 1995
)
1.73
" Doxazosin has the advantage of more convenient dosing (once daily) and unlike prazosin it does not produce orthostatic blood pressure falls; it is less toxic and better tolerated."( Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (Part One).
Dutkiewicz, S; Witeska, A, 1995
)
2.64
" The dose-response curves for collagen and ADP were unaffected by either drug."( The potentiation of adrenaline-induced in vitro platelet aggregation by ADP, collagen and serotonin and its inhibition by naftopidil and doxazosin in normal human subjects.
Alarayyed, NA; Graham, BR; Prichard, BN; Smith, CC, 1995
)
0.49
" The initial dosage was 1 mg for three days; afterwards, patients have been instructed to take a whole 2 mg tablet in the morning up to the following visit (i."( [Doxazosin in the treatment of light-to-moderate arterial hypertension in a non-comparative multicenter study].
Pessina, AC, 1995
)
1.2
" Six hypertensive men were treated with doxazosin starting at 1 mg/day, and the dosage was titrated at weekly intervals up to a maximum of 8 mg/day."( Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension.
Fujishima, M; Hirota, Y; Ito, Y; Takata, Y; Yoshizumi, T, 1995
)
0.82
" In a further 7-week period the dosage level reached with the initial drug was halved, and titration with the second agent was carried out."( Comparative and combined efficacy of doxazosin and enalapril in hypertensive patients.
Boutagy, J; Johnston, HJ; Marwood, JF; Monaghan, JC; Okoro, EO; Stokes, GS, 1994
)
0.56
" The dosage of doxazosin was, however, found to have no influence on the lipid-altering actions; a further study was therefore recommended."( The effects of doxazosin on plasma lipid and lipoprotein levels in hypertensive patients.
Agbedana, EO; Ahaneku, JE; Salako, LA; Taylor, GO; Walker, O,
)
0.84
"In this pilot study, the effect of dosing schedule on the efficacy and safety of the long-acting alpha 1-adrenergic blockers, terazosin (TER) and doxazosin (DOX), was evaluated in 43 consecutive normotensive men (mean age 59."( Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety.
Kaplan, SA; Olsson, CA; Soldo, KA, 1995
)
0.85
" After clinical and laboratory evaluation without treatment for at least two weeks, the two groups were treated with enalapril 5-10 or 20 mg daily plus doxazosin at the dosage of 1-2-4- or 8 mg daily; they were observed for 24 weeks."( [Evaluation of the efficacy and tolerance of doxazosin vs. enalapril inaged patients with light to moderate arterial hypertension].
Ansuini, R; Curnis, A; Gallucci, M; Malacco, E; Puddu, P; Pupita, F, 1995
)
0.75
" Terazosin, an alpha 1-adrenergic blocking agent, was given initially at the dosage of 1 mg daily."( Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension.
Angeli-Greaves, M; Armas Padilla, MC; Armas-Hernández, MJ; Carvajal, AR; Guerrero Pajuelo, J; Hernández Hernández, R, 1996
)
0.29
" Doxazosin, due to its symptomatic and uroflowmetric efficacy, favourable safety profile and simple dosing schedule has a place in the management of symptomatic BPH patients."( A comparative study of: long-term alpha-1-blocker, Doxazosin therapy versus surgery in the treatment of benign prostatic hyperplasia.
Dutkiewicz, S,
)
1.29
" Doxazosin reduced blood pressure without significant increase in heart rate and was, overall, well tolerated producing mild side effects not requiring withdrawal, or reduction in dosage of the drug in 6 cases."( Open trial of doxazosin in hypertensive Africans: dose finding, efficacy and safety studies.
Salako, LA; Sowunmi, A; Walker, O, 1996
)
1.56
" This retrospective analysis evaluated dosing regimens and drug acquisition costs for 101 patients identified from medical records in a large metropolitan hospital as having hypertension and/or benign prostatic hyperplasia and receiving alpha-blocker therapy with either doxazosin or terazosin."( Trends in alpha-blocker treatment of patients with benign prostatic hyperplasia and hypertension: dosing regimens and cost comparisons.
Raymond, JL; Smith, CS,
)
0.31
" Twenty-eight men (78%) were on other anti-hypertensive medication; the type and dosage were not changed during the study."( The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years.
Ikeguchi, E; Kaplan, SA; Santarosa, RP; Te, AE, 1997
)
0.3
" Patients with BPH who are already being treated for hypertension with doxazosin need no alteration in their dosage regimen, and doxazosin can be used as a single agent to treat both conditions."( Doxazosin for benign prostatic hyperplasia in primary care.
Guthrie, R,
)
1.81
"1 mumol/L) had no alpha 1-adrenoceptor antagonist effect but altered the mode of action of the alpha 1-adrenoceptor antagonist doxazosin: PD123319 changed doxazosin from a competitive to a non-competitive antagonist, as evidenced by the reduced slope of the dose-response curve for the alpha 1-adrenoceptor agonist phenylephrine."( Effect of angiotensin II receptor blockade on the interaction between enalaprilat and doxazosin in rat tail arteries.
Marwood, JF,
)
0.56
"008, respectively), consistent with a 24-hour once-daily dosing of doxazosin."( Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Multicenter Study Group.
Chung, M; Dias, N; Fawzy, A; Gaffney, M; Vashi, V, 1999
)
0.78
" The maximal therapeutic dosage of doxazosin would appear to be 8 mg in this group of BPH patients."( Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Multicenter Study Group.
Chung, M; Dias, N; Fawzy, A; Gaffney, M; Vashi, V, 1999
)
0.82
" While effects on isolated stromal cells are of undoubted importance, failure to demonstrate a consistent dose-response relationship between expression of smooth muscle cell phenotype and inhibition by doxazosin suggests that additional influences, including humoral factors as well as the proximity of differentiated epithelium, are also likely to be involved in this interaction in the intact tissue."( Influence of the alpha1-adrenergic antagonist, doxazosin, on noradrenaline-induced modulation of cytoskeletal proteins in cultured hyperplastic prostatic stromal cells.
Foster, CS; Ke, Y; Rhodes, NP; Smith, P, 1999
)
0.75
" Consideration should be given to increasing the dosage to 8 mg."( A randomized double-blind study assessing 4 versus 8 mg. doxazosin for benign prostatic hyperplasia.
Emery, RT; Ferguson, SF; Johnson, DE; MacDiarmid, SA; McGuirt-Franklin, R; McIntyre, WJ, 1999
)
0.55
" These findings indicate that the recommended dosing regimen for doxazosin is appropriate for patients with clinically mild to moderate hepatic impairment."( The effects of hepatic impairment on the pharmacokinetics of doxazosin.
Chung, M; Penenberg, D; Vashi, V; Walmsley, P, 2000
)
0.79
" We studied the effect of nighttime dosing of an alpha(1)-adrenergic blocker, doxazosin, on the BP dipping status of 118 hypertensives, all of whom underwent 24-hour ambulatory BP monitoring before and after treatment."( Changes of nocturnal blood pressure dipping status in hypertensives by nighttime dosing of alpha-adrenergic blocker, doxazosin : results from the HALT study.
Kario, K; Pickering, TG; Schwartz, JE, 2000
)
0.74
" After an upward titration period, patients were maintained on a fixed dosage of doxazosin (1 to 16 mg/day) or matching placebo for 4 weeks."( The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study.
Black, HR; Garofalo, JL; Sollins, JS, 2000
)
0.88
" Habitual smokers were randomized into two subgroups on the basis of the use of doxazosin, as follows: subgroup 1A (n = 7), without administration of doxazosin before catheterization; subgroup 1B (n = 7), with dosing doxazosin."( Distension of urinary bladder induces exaggerated coronary constriction in smokers with early atherosclerosis.
Chen, MF; Lee, CY; Lee, TM; Lee, YT; Su, SF; Suo, WY; Tsai, CH, 2000
)
0.53
" It should be stated that the described pharmacological differences of doxazosine GITS in younger and elderly, in female and male patients do not influence significantly initial dosing of the drug."( [Cardura XL--a unique drug formulation--doxazosine administered in a slow-release form (doxazosine GITS)].
Grzeszczak, W, 2000
)
0.81
" Among the 8 subjects in whom doxazosin dosage was increased to the maximum of 4 mg, the mean blood pressure achieved at 4 mg did not differ from that achieved at 2 mg (136/87 v 136/88 mm Hg)."( Low-dose alpha/beta blockade in the treatment of essential hypertension.
Gerber, LM; Mann, SJ, 2001
)
0.6
" The suggested methods were used to determine doxazosin mesylate and celecoxib in bulk powder, laboratory-prepared mixtures and pharmaceutical dosage forms (cardura tablet and celebrex capsule)."( Stability-indicating methods for the determination of doxazosin mezylate and celecoxib.
Abo-Talib, NF; Bebawy, LI; Moustafa, AA, 2002
)
0.82
" Following phenoxybenzamine therapy substantial a 1-adrenoceptor blockade, detected as a right shift of phenylephrine dose-response curves, persisted for more than 2 days postoperatively, whereas after doxazosin it was undetectable on the first postoperative day."( Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma.
Farndon, JR; Prys-Roberts, C, 2002
)
0.81
" Doxazosin GITS is an effective and well-tolerated treatment in patients with hypertension and/or BPH and without heart failure or clinical coronary heart disease and has advantages over doxazosin standard in terms of a simpler dosing regimen and improved tolerability."( Effect of doxazosin GITS on blood pressure in hypertensive and normotensive patients: a review of hypertension and BPH studies.
Kirby, RS; Lund-Johansen, P, 2003
)
1.63
" Dose-response curves for carbachol and isoproterenol showed a shift to the left in rat detrusor smooth muscles from partially obstructed bladder when compared with the results obtained in detrusor muscles from sham-operated bladder."( Doxazosin effects on cholinergic and adrenergic responses in rat isolated detrusor smooth muscle preparations from obstructed bladder.
Kukul, E; Usta, C; Yalçinkaya, M, 2004
)
1.77
"We conducted ambulatory BP monitoring three times (twice at baseline and after nighttime dosing of the alpha1-blocker doxazosin) in 98 elderly hypertensive patients in whom the presence of silent cerebral infarcts (SCI) was assessed by brain magnetic resonance imaging."( Morning blood pressure surge and hypertensive cerebrovascular disease: role of the alpha adrenergic sympathetic nervous system.
Eguchi, K; Hoshide, S; Hoshide, Y; Ishikawa, J; Kario, K; Morinari, M; Pickering, TG; Shimada, K, 2004
)
0.53
" Although the standard preparation is suitable for once-daily dosing in BPH, it has to be titrated through three steps to its final dose."( After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia.
Doggrell, SA, 2004
)
0.68
" Bedtime dosing with doxazosin GITS, however, significantly reduced BP throughout the 24h both when used as a monotherapy and when used in combination with other antihypertensive pharmacotherapy."( Administration-time-dependent effects of doxazosin GITS on ambulatory blood pressure of hypertensive subjects.
Ayala, DE; Calvo, C; Covelo, M; Domínguez, MJ; Fernández, JR; Fontao, MJ; Hermida, RC; López, JE, 2004
)
0.91
" Higher rates of twice-daily (or 2 units per day) dosing are associated with higher incremental cost-effectiveness ratios."( Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia.
Chrischilles, EA; Klein, RW; Kreder, KJ; Ohsfeldt, RL,
)
0.41
" Blood pressure (BP) and heart rate were recorded before dosing and for 24 hours after dosing."( Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men.
Bedding, A; Emmick, JT; Jackson, G; Kloner, RA; Mitchell, MI; Pereira, A; Warner, MR, 2004
)
0.55
" Meanwhile the number of pain episodes, analgesic dosage and the number of days for spontaneous passage of the calculi through the ureter were also recorded."( The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones.
Basar, H; Basar, MM; Batislam, E; Ferhat, M; Tuglu, D; Yilmaz, E, 2005
)
0.33
" Doxazosin GITS (Cardura XL, Cardular PP Uro, Diblocin PP Uro) has an altered pharmacokinetic profile, which allows a higher initial dosage to be used than with the standard formulation and less titration steps to reach a clinically effective dosage."( Doxazosin gastrointestinal therapeutic system: a review of its use in benign prostatic hyperplasia.
Goldsmith, DR; Plosker, GL, 2005
)
2.68
" DOX GITS dosage remained unchanged at 4 mg throughout the study."( Comparison of doxazosin GITS and standard doxazosin in the treatment of high blood pressure.
Os, I, 2006
)
0.69
" The clinical dosage for doxazosin GITS was estimated to be at least 8 mg and the stable pharmacological effect is expected based on the estimated receptor occupancy."( Assessment of alpha1-adrenoceptor antagonists in benign prostatic hyperplasia based on the receptor occupancy theory.
Ito, K; Ohtani, H; Sawada, Y, 2007
)
0.64
" At steady state the mean area under the curve for a dosing interval and elimination half-life were calculated to be 367."( Pharmacokinetics of doxazosin gastrointestinal therapeutic system after multiple administration in Korean healthy volunteers.
Chun, IK; Gwak, HS; Kwon, YH; Yoon, SJ, 2007
)
0.66
" The incidence of hypotension was low in healthy men given increasing doses of doxazosin with chronically dosed tadalafil or placebo."( Hemodynamic interaction between a daily dosed phosphodiesterase 5 inhibitor, tadalafil, and the alpha-adrenergic blockers, doxazosin and tamsulosin, in middle-aged healthy male subjects.
Darstein, C; Guillaume, M; Jimenez, MC; Lonsdale, F; Mitchell, MI, 2007
)
0.77
" The aim of this study was to clarify the add-on effects of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning blood pressure in patients with essential hypertension who were under long-acting calcium channel blocker amlodipine monotherapy."( Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy.
Gomi, T; Ikeda, T; Matsuda, N; Shibuya, Y; Shinozaki, S; Suzuki, Y, 2007
)
0.77
"Infravesical obstruction of the lower urinary tract was simulated in rats by dosed constriction of the prevesical portion of the urethra."( Heterogeneity of morphological and functional changes in various compartments of rat urinary bladder in infravesical obstruction of the urinary tract.
Belik, SM; Khromov, RA; Kirpatovskii, VI; Kudryavtsev, YV; Mudraya, IS, 2009
)
0.35
" Sometimes ionic interactions are preferred to prolong drug release from dosage forms in a controllable manner."( Interactions of biopolymers carrageenans with cationic drug doxazosin mesylate characterized by means of differential scanning calorimetry.
Baumgartner, S; Pavli, M; Vrecer, F, 2010
)
0.6
" The number of pain episodes, analgesic dosage and the number of days of spontaneous passage of the calculi through the ureter were also recorded."( Efficacy of three different alpha 1-adrenergic blockers and hyoscine N-butylbromide for distal ureteral stones.
Canat, L; Caskurlu, T; Gurbuz, MC; Kilic, M; Polat, H,
)
0.13
" Both number of colic episodes and analgesic dosage were significantly lower with tamsulosin as compared to control and doxazosin."( Tamsulosin and doxazosin as adjunctive therapy following shock-wave lithotripsy of renal calculi: randomized controlled trial.
Fareed, K; Fouda, K; Gaafar, S; Marzouk, E; Yakoubi, R; Zahran, AR; Zaytoun, OM, 2012
)
0.94
" The differences in binding of doxazosin to N- and Aform of albumin are an important factor, which may determines therapeutic dosage and toxicity of the test drug."( Analysis of Aged Human Serum Albumin Affinity for Doxazosin.
Chudzik, M; Pawelczak, B; Pożycka, J; Równicka-Zubik, J; Sulkowska, A, 2016
)
0.97
"To evaluate single and chronic dosing effects of doxazosin on nasal airflow and symptoms in allergic rhinitis."( Effects of the inverse alpha-agonist doxazosin in allergic rhinitis.
Lipworth, BJ; Manoharan, A; Morrison, AE, 2016
)
0.96
" The oxymetazoline dose-response for PNIF was blunted after single vs chronic dosing with doxazosin: mean difference -17 L/min (95% CI -30 to -4) P = 0."( Effects of the inverse alpha-agonist doxazosin in allergic rhinitis.
Lipworth, BJ; Manoharan, A; Morrison, AE, 2016
)
0.93
"There was a disconnect between single and chronic dosing effects of doxazosin for nasal symptoms, oxymetazoline response and cardiovascular outcomes, in turn suggesting alpha-1 receptor up-regulation."( Effects of the inverse alpha-agonist doxazosin in allergic rhinitis.
Lipworth, BJ; Manoharan, A; Morrison, AE, 2016
)
0.94
" The patients in the duloxetine group received doxazosin 4 mg + duloxetine 30 mg once a day, and the dosage of duloxetine was increased to 60 mg after a week."( Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome: An observational study.
Dong, D; Ji, Z; Li, H; Yan, S; Zhang, M, 2017
)
0.96
" Dosage of 8 mg/day doxazosin increased or normalized cortisol levels following stress imagery and decreased cortisol levels following neutral imagery."( Effect of doxazosin on stress reactivity and the ability to resist smoking.
Lavery, ME; McKee, SA; Oberleitner, LM; Picciotto, MR; Pittman, BP; Shi, JM; Smith, KM; Tetrault, JM; Verplaetse, TL; Weinberger, AH, 2017
)
1.18
"A new, selective and sensitive spectrofluorimetric method was designed for the quantitation of doxazosin (DOX), terazosin (TER) and alfuzosin (ALF) in their dosage forms and human plasma."( An efficient spectrofluorimetric method adopts doxazosin, terazosin and alfuzosin coupling with orthophthalaldehyde: Application in human plasma.
Derayea, SM; Hammad, MA; Mohamed, AA; Mohamed, AI; Omar, MA, 2018
)
0.96
" Additional dose-response analyses were carried out."( Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease.
Liu, L; Narayanan, NS; Pottegård, A; Simmering, JE; Welsh, MJ, 2021
)
0.62
" Orthostatic hypotension is a concern with the use of α1-blockers especially in the elderly, and requires careful initial bedtime dosing and avoiding overdosing."( Role of α1-blockers in the current management of hypertension.
Buranakitjaroen, P; Cheng, HM; Chia, YC; Kario, K; Li, H; Li, Y; Sogunuru, GP; Tay, JC; Van Huynh, M; Wang, JG; Wang, TD; Xu, TY, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
alpha-adrenergic antagonistAn agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
vasodilator agentA drug used to cause dilation of the blood vessels.
antihyperplasia drugA drug used for the treatment of hyperplasia (increaced cell production within an organ or tissue).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
quinazolinesAny organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.
N-acylpiperazine
N-arylpiperazine
benzodioxineAny organic heterobicyclic compound containing ortho-fused benzene and dioxine rings.
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
aromatic amineAn amino compound in which the amino group is linked directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (36)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency29.28570.100020.879379.4328AID488772; AID588453; AID588456
ATAD5 protein, partialHomo sapiens (human)Potency23.09990.004110.890331.5287AID493107
USP1 protein, partialHomo sapiens (human)Potency11.22020.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency20.38650.000811.382244.6684AID686978; AID686979
EWS/FLI fusion proteinHomo sapiens (human)Potency21.19870.001310.157742.8575AID1259253; AID1259255; AID1259256
IDH1Homo sapiens (human)Potency25.11890.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency26.67950.035520.977089.1251AID504332
D(1A) dopamine receptorHomo sapiens (human)Potency10.82670.02245.944922.3872AID488982; AID488983
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID488953
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency18.89480.00378.618923.2809AID2667; AID2668
Alpha-synucleinHomo sapiens (human)Potency5.62340.56239.398525.1189AID652106
D(1A) dopamine receptorSus scrofa (pig)Potency26.12160.00378.108123.2809AID2667
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-1A adrenergic receptorOryctolagus cuniculus (rabbit)Ki0.00320.00000.02040.2512AID36753
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)IC50 (µMol)0.54400.00011.00768.7800AID625218
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)Ki0.28500.00000.887110.0000AID625218
Interstitial collagenaseHomo sapiens (human)IC50 (µMol)5.74900.00020.850210.0000AID625177
Beta-2 adrenergic receptorHomo sapiens (human)IC50 (µMol)2.74800.00020.93267.2000AID625205
Beta-2 adrenergic receptorHomo sapiens (human)Ki1.88900.00000.66359.5499AID625205
Alpha-2A adrenergic receptorHomo sapiens (human)Ki0.72900.00010.807410.0000AID35952
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)IC50 (µMol)2.21550.00001.612910.0000AID625171
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)Ki1.81510.00042.03378.6606AID625171
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki0.00150.00010.949010.0000AID257359; AID35266; AID422825
Alpha-2B adrenergic receptorHomo sapiens (human)Ki5.00000.00020.725710.0000AID36231
Alpha-1A adrenergic receptorBos taurus (cattle)Ki0.72900.00000.50723.7020AID35952
Alpha-2C adrenergic receptorHomo sapiens (human)Ki0.28000.00030.483410.0000AID36408
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)Ki0.00120.00000.929610.0000AID35328
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)Ki0.00120.00000.970810.0000AID35328
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)Ki0.00120.00000.937510.0000AID35328
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)Ki0.00200.00000.575110.0000AID35266
Alpha-1D adrenergic receptorHomo sapiens (human)IC50 (µMol)0.00340.00020.75688.8970AID625200
Alpha-1D adrenergic receptorHomo sapiens (human)Ki0.00150.00000.360910.0000AID1507226; AID257359; AID35328; AID35468; AID422826; AID625200
5-hydroxytryptamine receptor 2CHomo sapiens (human)IC50 (µMol)0.54400.00011.03029.0000AID625218
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki0.28500.00010.954910.0000AID625218
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)2.68800.00010.86458.7096AID625222
Sodium-dependent serotonin transporterHomo sapiens (human)Ki1.42800.00000.70488.1930AID625222
Alpha-1A adrenergic receptorHomo sapiens (human)Ki0.00150.00000.272610.0000AID1507224; AID257357; AID36618; AID36753; AID422824
Alpha-1B adrenergic receptorHomo sapiens (human)Ki0.00080.00000.471310.0000AID1507225; AID257358; AID37335; AID37478; AID422825
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)0.36800.00011.18738.9125AID625217
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.23400.00030.769310.0000AID625217
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00070.00001.819410.0000AID1493872
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki0.00200.00000.965010.0000AID35266
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)0.18800.00071.841946.0000AID625256
Sodium-dependent dopamine transporter Homo sapiens (human)Ki0.14900.00021.11158.0280AID625256
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)1.40220.00091.901410.0000AID576612; AID625171
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)Ki1.81510.00211.840710.0000AID625171
Nuclear receptor subfamily 3 group C member 3 Bos taurus (cattle)IC50 (µMol)2.21550.10482.83988.3173AID625171
Nuclear receptor subfamily 3 group C member 3 Bos taurus (cattle)Ki1.81510.08582.95428.6606AID625171
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Kd0.00200.00020.51397.5858AID422827
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-1D adrenergic receptorHomo sapiens (human)EC40 (µMol)0.03230.00450.01640.0500AID36259
Alpha-1A adrenergic receptorHomo sapiens (human)EC40 (µMol)0.03230.00450.01640.0500AID36259
Alpha-1B adrenergic receptorHomo sapiens (human)EC40 (µMol)0.03230.00450.01640.0500AID36259
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (294)

Processvia Protein(s)Taxonomy
proteolysisInterstitial collagenaseHomo sapiens (human)
protein metabolic processInterstitial collagenaseHomo sapiens (human)
extracellular matrix disassemblyInterstitial collagenaseHomo sapiens (human)
collagen catabolic processInterstitial collagenaseHomo sapiens (human)
positive regulation of protein-containing complex assemblyInterstitial collagenaseHomo sapiens (human)
cellular response to UV-AInterstitial collagenaseHomo sapiens (human)
extracellular matrix organizationInterstitial collagenaseHomo sapiens (human)
diet induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
regulation of sodium ion transportBeta-2 adrenergic receptorHomo sapiens (human)
transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorHomo sapiens (human)
smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
cell surface receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
endosome to lysosome transportBeta-2 adrenergic receptorHomo sapiens (human)
response to coldBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase A signalingBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of bone mineralizationBeta-2 adrenergic receptorHomo sapiens (human)
heat generationBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorHomo sapiens (human)
bone resorptionBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of mini excitatory postsynaptic potentialBeta-2 adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of lipophagyBeta-2 adrenergic receptorHomo sapiens (human)
cellular response to amyloid-betaBeta-2 adrenergic receptorHomo sapiens (human)
response to psychosocial stressBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of AMPA receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-1A adrenergic receptorBos taurus (cattle)
positive regulation of MAPK cascadeAlpha-1A adrenergic receptorBos taurus (cattle)
regulation of cardiac muscle contractionAlpha-1A adrenergic receptorBos taurus (cattle)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
apoptotic processAlpha-1A adrenergic receptorHomo sapiens (human)
smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
activation of phospholipase C activityAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1A adrenergic receptorHomo sapiens (human)
adult heart developmentAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of cell population proliferationAlpha-1A adrenergic receptorHomo sapiens (human)
response to xenobiotic stimulusAlpha-1A adrenergic receptorHomo sapiens (human)
response to hormoneAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of autophagyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of action potentialAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
calcium ion transport into cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
cell growth involved in cardiac muscle cell developmentAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase C signalingAlpha-1A adrenergic receptorHomo sapiens (human)
pilomotor reflexAlpha-1A adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-1B adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of cardiac muscle contractionAlpha-1B adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1B adrenergic receptorHomo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (83)

Processvia Protein(s)Taxonomy
endopeptidase activityInterstitial collagenaseHomo sapiens (human)
metalloendopeptidase activityInterstitial collagenaseHomo sapiens (human)
serine-type endopeptidase activityInterstitial collagenaseHomo sapiens (human)
peptidase activityInterstitial collagenaseHomo sapiens (human)
zinc ion bindingInterstitial collagenaseHomo sapiens (human)
amyloid-beta bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase bindingBeta-2 adrenergic receptorHomo sapiens (human)
potassium channel regulator activityBeta-2 adrenergic receptorHomo sapiens (human)
identical protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-2 adrenergic receptorHomo sapiens (human)
protein-containing complex bindingBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-2 adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1A adrenergic receptorBos taurus (cattle)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1B adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1B adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1B adrenergic receptorHomo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (56)

Processvia Protein(s)Taxonomy
extracellular regionInterstitial collagenaseHomo sapiens (human)
extracellular matrixInterstitial collagenaseHomo sapiens (human)
extracellular spaceInterstitial collagenaseHomo sapiens (human)
nucleusBeta-2 adrenergic receptorHomo sapiens (human)
lysosomeBeta-2 adrenergic receptorHomo sapiens (human)
endosomeBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptorHomo sapiens (human)
Golgi apparatusBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
endosome membraneBeta-2 adrenergic receptorHomo sapiens (human)
membraneBeta-2 adrenergic receptorHomo sapiens (human)
apical plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneBeta-2 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-2 adrenergic receptorHomo sapiens (human)
receptor complexBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
nucleusAlpha-1A adrenergic receptorBos taurus (cattle)
cytoplasmAlpha-1A adrenergic receptorBos taurus (cattle)
plasma membraneAlpha-1A adrenergic receptorBos taurus (cattle)
caveolaAlpha-1A adrenergic receptorBos taurus (cattle)
nuclear membraneAlpha-1A adrenergic receptorBos taurus (cattle)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
nucleusAlpha-1A adrenergic receptorHomo sapiens (human)
nucleoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
caveolaAlpha-1A adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
nucleusAlpha-1B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
caveolaAlpha-1B adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (192)

Assay IDTitleYearJournalArticle
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID247991Inhibition of prostate cancer (PC-3) cell proliferation2004Journal of medicinal chemistry, Aug-26, Volume: 47, Issue:18
Pharmacological exploitation of the alpha1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation.
AID1507226Displacement of [3H]prazosin from human alpha1D adrenoceptor expressed in CHO cell membranes after 30 mins2017European journal of medicinal chemistry, Aug-18, Volume: 136Quinazoline based α
AID195503Percent reduction in blood pressure in spontaneously hypertensive rats (SHR) at peroral dose of 5 mg/kg was determined after 1 hr1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
2,4-diamino-6,7-dimethoxyquinazolines. 1. 2-[4-(1,4-benzodioxan-2-ylcarbonyl)piperazin-1-yl] derivatives as alpha 1-adrenoceptor antagonists and antihypertensive agents.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID195504Percent reduction in blood pressure in spontaneously hypertensive rats (SHR) at peroral dose of 5 mg/kg was determined after 6 hr1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
2,4-diamino-6,7-dimethoxyquinazolines. 1. 2-[4-(1,4-benzodioxan-2-ylcarbonyl)piperazin-1-yl] derivatives as alpha 1-adrenoceptor antagonists and antihypertensive agents.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID232246Selectivity ratio (antolog[pA2rat vas deferens/pA2 rat spleen]) of the compound2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
AID36259Antagonist activity against post junctional alpha-1 adrenergic receptor was measured by Kerbs super fused rabbit pulmonary artery preparations labeled with [3H]- norepinephrine.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
2,4-diamino-6,7-dimethoxyquinazolines. 1. 2-[4-(1,4-benzodioxan-2-ylcarbonyl)piperazin-1-yl] derivatives as alpha 1-adrenoceptor antagonists and antihypertensive agents.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID36753Binding affinity was tested on human Alpha-1A adrenergic receptor1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Pharmacological options in the treatment of benign prostatic hyperplasia.
AID257365Maximum response towards cloned human 5HT1A receptor2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4-chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subt
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID29127Antagonist dissociation constant in rat vas deferens2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).
AID1493870Binding affinity to EphA2 in human MDA-MB-231 cells assessed as induction of EphA2 receptor internalization at 50 uM after 1 hr by immunofluorescence microscopy2018European journal of medicinal chemistry, Jan-01, Volume: 143Design and synthesis of small molecule agonists of EphA2 receptor.
AID1507235Induction of necrosis in human LNCAP cells assessed as loss of plasma membrane integrity at 1 to 10 uM after 24 hrs by trypan blue staining-based Neubauer hemocytometric method2017European journal of medicinal chemistry, Aug-18, Volume: 136Quinazoline based α
AID1202269Cytotoxicity against human LNCAP cells after 48 hrs by WST-8 assay2015European journal of medicinal chemistry, , Volume: 96Novel naftopidil-related derivatives and their biological effects as alpha1-adrenoceptors antagonists and antiproliferative agents.
AID36469In vitro antagonistic activity against alpha-1A receptor in dog prostate.2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
AID1507225Displacement of [3H]prazosin from human alpha1B adrenoceptor expressed in CHO cell membranes after 30 mins2017European journal of medicinal chemistry, Aug-18, Volume: 136Quinazoline based α
AID62833Intraurethral pressure (IUP) in Beagle dogs values are expressed as pseudo pA2 values.2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).
AID422825Displacement of [3H]prazosin from human Alpha-1B adrenoceptor expressed in CHO cells2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID422824Displacement of [3H]prazosin from human alpha1A adrenoceptor expressed in CHO cells2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.
AID232245Selectivity ratio (antolog[pA2 of IUP-pED50 of SHR]) of the compound2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID36231Binding affinity against Alpha-2B adrenergic receptor from human clones.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID257358Displacement of [3H]prazosin from cloned human ADRA1B expressed in CHO cells2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4-chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subt
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID197367Antagonistic activity in spontaneously hypertensive rat model.2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
AID239799Binding affinity for alpha 1a adrenoceptor2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Range and sensitivity as descriptors of molecular property spaces in dynamic QSAR analyses.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID257364Agonist efficacy towards cloned human 5HT1A receptor by [35SGTP]gammaS binding in HeLa cells2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4-chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subt
AID1507240Induction of apoptosis in human LNCAP cells assessed as increase in DNA fragmentation at 10 uM after 24 hrs by spectrophotometer relative to control2017European journal of medicinal chemistry, Aug-18, Volume: 136Quinazoline based α
AID239801Binding affinity for alpha 1d adrenoceptor2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Range and sensitivity as descriptors of molecular property spaces in dynamic QSAR analyses.
AID1053266Agonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as stimulation of cAMP accumulation at 100 uM after 30 mins by HTRF assay relative to SKF812972013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID37033In vitro antagonistic activity towards alpha-1A adrenergic receptor in rat vas deferens2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
AID422843Antiangiogenic activity in human PC3 cells xenografted in NU/NU mouse assessed as reduction vascularization at 3 mg/kg by immunohistochemistry2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.
AID1507231Antiproliferative activity against human PC3 cells after 120 hrs by MTT assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Quinazoline based α
AID1053262Agonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin at 100 uM by luminometric analysis relative to quinpirol2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID422836Induction of apoptosis in human LNCAP cells assessed as caspase 3/7 activation after 24 hrs Caspase-Glo 3/7 assay2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1229079Cytotoxicity against HEK293A cells transfected with alpha-1D adrenergic receptor assessed as cell viability by sulforhodamine B assay2015ACS medicinal chemistry letters, May-14, Volume: 6, Issue:5
Discovery of Quinazoline-Based Fluorescent Probes to α1-Adrenergic Receptors.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID35328Binding affinity against Alpha-1D adrenergic receptor, from human clones.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID422837Induction of apoptosis in human NHDF cells assessed as caspase 3/7 activation after 24 hrs Caspase-Glo 3/7 assay2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.
AID391760Cytotoxicity against human PC3 cells after 48 hrs by SRB assay2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Structure-activity relationships in 1,4-benzodioxan-related compounds. 9. From 1,4-benzodioxane to 1,4-dioxane ring as a promising template of novel alpha1D-adrenoreceptor antagonists, 5-HT1A full agonists, and cytotoxic agents.
AID547804Selectivity window, ratio of EC50 for BESM cells to EC50 for Trypanosoma cruzi amastigotes infected in BESM cells2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID257363ADRA1D blocking activity assessed by antagonism of (-)-NE induced contractions on isolated rat thoracic aorta2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4-chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subt
AID422831Cytotoxicity against human DU145 cells after 72 hrs by CellTitter-Glo luminescent cell viability assay2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.
AID29125Antagonist dissociation constant in rat spleen2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID36506Antagonist activity against prejunctional alpha-2 adrenergic receptor was measured by Kerbs super fused rabbit pulmonary artery preparations labeled with [3H]- norepinephrine; NA means no activity1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
2,4-diamino-6,7-dimethoxyquinazolines. 1. 2-[4-(1,4-benzodioxan-2-ylcarbonyl)piperazin-1-yl] derivatives as alpha 1-adrenoceptor antagonists and antihypertensive agents.
AID35266Compound was tested for its binding affinity for alpha-1 adrenergic receptor site by displacement of [3H]clonidine at 10e-6 M concentration1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
2,4-diamino-6,7-dimethoxyquinazolines. 1. 2-[4-(1,4-benzodioxan-2-ylcarbonyl)piperazin-1-yl] derivatives as alpha 1-adrenoceptor antagonists and antihypertensive agents.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID547621Cytotoxicity against BESM cells after 88 hrs by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID422840Antitumor activity against human PC3 cells xenografted in NU/NU mouse at 10 mg/kg, po after 21 days relative to control2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID37252Tested for its binding affinity for alpha-2 adrenergic receptor site by displacement of [3H]clonidine at 10e-6 M concentration; NA means no activity1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
2,4-diamino-6,7-dimethoxyquinazolines. 1. 2-[4-(1,4-benzodioxan-2-ylcarbonyl)piperazin-1-yl] derivatives as alpha 1-adrenoceptor antagonists and antihypertensive agents.
AID36124pA2 for Alpha-1 adrenergic receptor from human prostate.1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Pharmacological options in the treatment of benign prostatic hyperplasia.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1493872Displacement of [3H]-prazosin from rat alpha1A adrenergic receptor after 60 mins by scintillation counting analysis2018European journal of medicinal chemistry, Jan-01, Volume: 143Design and synthesis of small molecule agonists of EphA2 receptor.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID36618Binding affinity against Alpha-1A adrenergic receptor from human clone1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID422833Cytotoxicity against human NHDF cells after 72 hrs by CellTitter-Glo luminescent cell viability assay2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID37335Binding affinity against Alpha-1B adrenergic receptor from human clone1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID62832In vivo antagonist dissociation constant in intaraurethral pressure model in dogs.2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
AID257361ADRA1A blocking activity assessed by antagonism of (-)-NE induced contractions on isolated rat prostatic vas deferens2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4-chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subt
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID422827Antagonist activity at rat alpha1A adrenoceptor assessed as inhibition if norepinephrine-induced contraction of vas deference2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID422828Antagonist activity at rat Alpha-1B adrenoceptor assessed as inhibition if phenylephrine-induced contraction of spleen2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.
AID1507232Antiproliferative activity against human LNCAP cells after 120 hrs by MTT assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Quinazoline based α
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID29813Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID36408Binding affinity against Alpha-2C adrenergic receptor from human clones.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID422834Induction of apoptosis in human PC3 cells assessed as caspase 3/7 activation after 24 hrs by Caspase-Glo 3/7 assay2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.
AID1202268Cytotoxicity against human DU145 cells after 48 hrs by WST-8 assay2015European journal of medicinal chemistry, , Volume: 96Novel naftopidil-related derivatives and their biological effects as alpha1-adrenoceptors antagonists and antiproliferative agents.
AID422842Induction of apoptosis in human PC3 cells xenografted in NU/NU mouse assessed as DNA fragmentation at 0.3 to 3 mg/kg by agarose gel electrophoresis2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.
AID422835Induction of apoptosis in human DU145 cells assessed as caspase 3/7 activation after 24 hrs Caspase-Glo 3/7 assay2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1507224Displacement of [3H]prazosin from human alpha1A adrenoceptor expressed in CHO cell membranes after 30 mins2017European journal of medicinal chemistry, Aug-18, Volume: 136Quinazoline based α
AID36505Antagonist activity against prejunctional alpha alpha-2 adrenergic receptor was measured by Kerbs super fused rabbit pulmonary artery preparations labeled with [3H]- norepinephrine.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
2,4-diamino-6,7-dimethoxyquinazolines. 1. 2-[4-(1,4-benzodioxan-2-ylcarbonyl)piperazin-1-yl] derivatives as alpha 1-adrenoceptor antagonists and antihypertensive agents.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID37478Binding affinity was tested on human Alpha-1B adrenergic receptor1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Pharmacological options in the treatment of benign prostatic hyperplasia.
AID35952Binding affinity against Alpha-2A adrenergic receptor, from human clones.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID257366Cytotoxic activity on human PC3 prostate cancer cells by SRB assay2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4-chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subt
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID679585TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1 uM, Doxazosin: 50 uM) in MDR1-expressing LLC-PK1 cells2002Life sciences, Feb-15, Volume: 70, Issue:13
Interaction of digoxin with antihypertensive drugs via MDR1.
AID197369Determination Pseudo pED50 in Spontaneously Hypertensive Rat (SHR) model2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).
AID29123Antagonist dissociation constant in dog prostate2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).
AID422830Cytotoxicity against human PC3 cells after 72 hrs by CellTitter-Glo luminescent cell viability assay2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.
AID547622Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID723774Cytotoxicity against human PC3 cells assessed as concentration required for tumor growth inhibition after 48 hrs by sulforhodamine B assay2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Structure-activity relationships in 1,4-benzodioxan-related compounds. 11. (1) reversed enantioselectivity of 1,4-dioxane derivatives in α1-adrenergic and 5-HT1A receptor binding sites recognition.
AID422832Cytotoxicity against human LNCAP cells after 72 hrs by CellTitter-Glo luminescent cell viability assay2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID257359Displacement of [3H]prazosin from cloned human ADRA1D expressed in CHO cells2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4-chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subt
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID35468Binding affinity was tested on human Alpha-1D adrenergic receptor1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Pharmacological options in the treatment of benign prostatic hyperplasia.
AID1507230Antiproliferative activity against human DU145 cells after 120 hrs by MTT assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Quinazoline based α
AID422839Antitumor activity against human PC3 cells xenografted in NU/NU mouse at 3 mg/kg, po after 21 days relative to control2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID422826Displacement of [3H]prazosin from human Alpha-1D adrenoceptor expressed in CHO cells2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.
AID257362ADRA1B blocking activity assessed by antagonism of (-)-phenylephrine induced contractions on isolated rat spleen2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4-chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subt
AID35155In vitro antagonistic activity against alpha-1B receptor in rat spleen.2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
AID723780Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Structure-activity relationships in 1,4-benzodioxan-related compounds. 11. (1) reversed enantioselectivity of 1,4-dioxane derivatives in α1-adrenergic and 5-HT1A receptor binding sites recognition.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID239800Binding affinity for alpha 1b adrenoceptor2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Range and sensitivity as descriptors of molecular property spaces in dynamic QSAR analyses.
AID1229078Cytotoxicity against HEK293A cells transfected with alpha-1A adrenergic receptor assessed as cell viability by sulforhodamine B assay2015ACS medicinal chemistry letters, May-14, Volume: 6, Issue:5
Discovery of Quinazoline-Based Fluorescent Probes to α1-Adrenergic Receptors.
AID257357Displacement of [3H]prazosin from cloned human ADRA1A expressed in CHO cells2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4-chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subt
AID422829Antagonist activity at rat Alpha-1D adrenoceptor assessed as inhibition if norepenephrine-induced contraction of thoracic aorta2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.
AID257360Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from cloned human 5HT1A receptor expressed in HeLa cells2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4-chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subt
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1202267Cytotoxicity against human PC3 cells after 48 hrs by WST-8 assay2015European journal of medicinal chemistry, , Volume: 96Novel naftopidil-related derivatives and their biological effects as alpha1-adrenoceptors antagonists and antiproliferative agents.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1053260Antagonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin assessed as inhibition of agonist-induced effect at 50 uM after 15 mins by luminometric analysis relative to haloperidol2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID36509Antagonist activity against prejunctional alpha-2 adrenergic receptor was measured by Kerbs super fused rabbit pulmonary artery preparations labeled with [3H]- norepinephrine; NA means no activity1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
2,4-diamino-6,7-dimethoxyquinazolines. 1. 2-[4-(1,4-benzodioxan-2-ylcarbonyl)piperazin-1-yl] derivatives as alpha 1-adrenoceptor antagonists and antihypertensive agents.
AID257369Inhibition of NE-induced increase of PC3 cell proliferation using ELISA BrdU2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4-chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subt
AID1053264Antagonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as inhibition of agonist-induced cAMP accumulation at 100 uM preincubated for 10 mins prior to agonist addition measured after 30 mins by HTRF assay relative t2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID294856Dissociation constant, pKa of the compound2007Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8
Computational approach to the basicity of a series of alpha1-adrenoceptor ligands in aqueous solution.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,288)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990130 (10.09)18.7374
1990's335 (26.01)18.2507
2000's498 (38.66)29.6817
2010's267 (20.73)24.3611
2020's58 (4.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 105.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index105.75 (24.57)
Research Supply Index7.50 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index196.13 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (105.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials439 (32.00%)5.53%
Reviews120 (8.75%)6.00%
Case Studies66 (4.81%)4.05%
Observational4 (0.29%)0.25%
Other743 (54.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (54)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients [NCT02563405]Phase 2/Phase 330 participants (Anticipated)Interventional2015-09-30Recruiting
Randomized Controlled Trial of Preoperative Alpha Blockade for Pheochromocytoma [NCT03176693]Phase 339 participants (Actual)Interventional2017-05-05Completed
Pheochromocytoma Randomised Study Comparing Adrenoreceptor Inhibiting Agents for Preoperative Treatment [NCT01379898]Phase 4134 participants (Actual)Interventional2011-12-31Completed
Cook Ureteral Stent Study [NCT03043612]56 participants (Actual)Interventional2015-06-10Completed
Beta-blocker Effect on Structural Remodeling and Gene Expression in the Failing Human Heart [NCT01798992]Phase 456 participants (Actual)Interventional2000-09-30Completed
A Phase 1, Single-centre, Double-blind, Randomized, Placebo-controlled, Two-cohort, Two-period Crossover Study of the Hemodynamic Interactions Between Avanafil and Two α-Adrenergic Blockers, Doxazosin and Tamsulosin, in Middle-aged Healthy Male Subjects [NCT01100021]Phase 148 participants (Actual)Interventional2010-02-28Completed
A Post Marketing Surveillance Study To Determine The Safety, Tolerability And Effectiveness Of Doxazosin Mesylate GITS Among Filipino Adult Males With Benign Prostatic Hyperplasia (BPH) [NCT01003886]989 participants (Actual)Observational2009-05-31Completed
A Parallel Group Study With Three Different α-antagonists and Placebo Once Daily Over Three Weeks to Assess Their Influence on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Voluntee [NCT02266537]Phase 197 participants (Actual)Interventional2005-11-30Completed
A Pilot Study to Assess the Effects of Doxazosin on Polysomnography in PTSD [NCT01959022]Phase 415 participants (Actual)Interventional2013-10-31Completed
A Randomized, Double-Blind, Placebo-Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in Post-Traumatic Stress [NCT03339258]Phase 280 participants (Anticipated)Interventional2018-04-15Recruiting
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
Treating Nightmares in Posttraumatic Stress Disorder With the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibility Study (ClonDoTrial) [NCT05360953]Phase 2189 participants (Anticipated)Interventional2022-04-06Recruiting
The Effects of Doxazosin Gastrointestinal Therapeutic System (GITS) on Ambulatory Blood Pressure and Cardiovascular Risk Factors in Uncontrolled Hypertensives on Drug Therapy [NCT00646841]Phase 489 participants (Actual)Interventional2003-02-28Completed
Evaluation of Alfuzosin as Medical Expulsion Therapy for Ureteral Stones [NCT00713739]Phase 3240 participants (Anticipated)Interventional2008-01-31Recruiting
Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment [NCT00741585]Phase 421,983 participants (Actual)Interventional2008-09-01Completed
A Prospective Study for the Effects of Chronic Use of Doxazosin on Alpha 1-adrenergic Receptors in Men With Benign Prostatic Hyperplasia [NCT00730418]25 participants (Actual)Interventional2007-01-31Completed
On the Antithrombotic Effects of Doxazosin and Ramipril in Essential Hypertension [NCT02901977]Phase 471 participants (Actual)Interventional2011-03-31Completed
Interactive Effects of Doxazosin and 3,4-Methylenedioxymethamphetamine (MDMA) in Healthy Subjects [NCT01386177]Phase 116 participants (Actual)Interventional2011-07-31Completed
The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia: A Prospective Randomized Multicenter Trial [NCT00687388]Phase 40 participants (Actual)Interventional2008-05-31Withdrawn(stopped due to in order to prepare a new clinical trial to evaluate with pathological change)
[NCT00000522]Phase 20 participants Interventional1985-08-31Completed
"Comparison of the Efficacy and Safety of Combination Treatment With Doxazosin Plus TolterodineSR 2 mg vs Doxazosin Plus TolterodineSR 4 mg in Men With an OAB/BPO: Randomized Controlled Study" [NCT00922506]Phase 483 participants (Actual)Interventional2009-05-31Completed
The Effects of Doxazosin on the Cardiovascular and Subjective Effects of Cocaine [NCT01062945]Phase 113 participants (Actual)Interventional2010-01-31Completed
A Proof of Concept Study in Allergic Rhinitis, to Evaluate the Differential Effects Between Single and Chronic Dosing of Doxazosin on Nasal Airway Calibre [NCT01946035]Phase 417 participants (Actual)Interventional2013-09-30Completed
Pharmacological Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment [NCT00006294]37,939 participants (Actual)Observational1999-09-30Completed
A Focus on Alpha-1 Blockade as a Novel Pharmacological Treatment for AUD [NCT04135846]Phase 2184 participants (Anticipated)Interventional2019-12-19Recruiting
A Prospective, Open-Labeled Trial of the Safety and Efficacy of Doxazosin GITS in Patients With Benign Prostate Hyperplasia [NCT00648323]Phase 480 participants (Actual)Interventional2003-11-30Completed
Clinical Efficacy of Doxazosin for Psychostimulant Dependence [NCT01371851]Phase 1/Phase 222 participants (Actual)Interventional2011-06-30Completed
CAP - Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders [NCT02500602]Phase 2144 participants (Actual)Interventional2016-06-01Completed
Doxazosin as a Potential Treatment for Methamphetamine Dependence [NCT02785393]Phase 111 participants (Actual)Interventional2011-03-31Completed
Phase 1, Open-Label, Randomized, Single-Dose, 3-Way Crossover Study Assessing Bioequivalence Of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition [NCT01389609]Phase 124 participants (Actual)Interventional2011-07-31Completed
Intensive Non-Sympathetic Activating Vasodilatory Treatment in Hypertensive Patients With Microvascular Angina Pectoris [NCT00424801]10 participants (Actual)Interventional2007-01-31Terminated(stopped due to Due to recent findings relating MRI contrast to nephrogenic systemic fibrosis)
Effects of Combination Therapy With an α1-blocker (Sustained-release Preparation of Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in the Treatment of Patients With Mild to Moderate Essential Hypertension [NCT00130156]Phase 493 participants (Actual)Interventional2005-10-31Completed
Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy [NCT00295555]Phase 498 participants (Actual)Interventional2004-01-31Completed
Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily in the Successful Rate of Trial Without Catheter in Acute Urinary Retention With Long Term Follow up [NCT00563485]120 participants (Anticipated)Interventional2005-10-31Terminated
Medical Therapy of Prostatic Symptoms [NCT00021814]Phase 33,407 participants (Actual)Interventional1995-12-31Completed
Targeting Stress-Induced Alcohol Relapse Risk With Doxazosin XL [NCT03398252]Phase 10 participants (Actual)Interventional2022-05-12Withdrawn(stopped due to No funding)
Black Education and Treatment of Hypertension (BEAT HTN) [NCT00661895]Phase 499 participants (Actual)Interventional2005-08-31Completed
Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. [NCT00535925]Phase 4850 participants (Actual)Interventional2005-10-31Completed
Doxazosin, An Alpha-1 Adrenergic Antagonist, for Cocaine Dependence: Pilot Study [NCT00880997]Phase 135 participants (Actual)Interventional2009-09-30Completed
Pharmacogenetic Trial of Noradrenergic Medication for Treatment of Cocaine Abuse [NCT01953432]Phase 243 participants (Actual)Interventional2014-04-01Completed
The Effects of Controlling Morning Hypertension on Target Organ Damage With Adrenergic Blockers, Based on Self-Measured Morning Blood Pressure Readings [NCT00285519]Phase 4600 participants Interventional2003-08-31Completed
Prognostic Value of Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy in Relation to Risk (the MAPEC Study). [NCT00295542]Phase 43,344 participants (Actual)Interventional2000-03-31Completed
Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy [NCT01435954]13,551 participants (Actual)Observational2010-08-31Completed
Doxazosin an a1 Antagonist for Alcohol Dependence [NCT01437046]Phase 248 participants (Actual)Interventional2011-11-30Completed
DOXAZOSIN AS A TREATMENT FOR POST TRAUMATIC STRESS SYNDROME [NCT02308202]Phase 130 participants (Actual)Interventional2012-01-31Completed
Influence of the Autonomic Nervous System on Endothelial Function as an Acute Response to Exercise in Hypertensive Individuals: a Randomized Double-blind Protocol Study [NCT04371757]39 participants (Anticipated)Interventional2020-04-30Recruiting
Complementary Combination Therapy for Cocaine Dependence [NCT02538744]Phase 145 participants (Actual)Interventional2015-08-31Completed
Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes? [NCT01730846]Phase 235 participants (Actual)Interventional2013-02-28Completed
[NCT00000542]Phase 30 participants Interventional1993-08-31Completed
Randomized Controlled Trial Targeting Noradrenergic Stress Mechanisms in Alcoholism With Doxazosin [NCT02989493]Phase 261 participants (Actual)Interventional2017-04-12Completed
Optimum Treatment for Drug-Resistant Hypertension [NCT02369081]Phase 4348 participants (Actual)Interventional2009-05-31Active, not recruiting
COX-2 Inhibitor Reduces Serum PSA Levels Might Predict a Lower Risk of Prostatic Cancer in Men With LUTS/BPH With an Elevated PSA Level [NCT01678313]Phase 2140 participants (Actual)Interventional2012-08-31Completed
H-26605: Pharmacogenetics of Doxazosin for Cocaine Dependence [NCT01145183]Phase 296 participants (Actual)Interventional2010-03-31Completed
Antimuscarinics as the First-line Treatment for Male With International Prostate Symptom Score (IPSS) Voiding-to-storage Subscore Rati (IPSS-V/S)≤1-- A Prospective Randomized Study Comparing With α-blockers [NCT01661621]Phase 4395 participants (Actual)Interventional2012-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00535925 (2) [back to overview]"Number of Participants Who Achieved of BP, HbA1c and Total, HDL and LDL Cholesterol Goals at the End of Intervention Phase"
NCT00535925 (2) [back to overview]"Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)"
NCT00661895 (1) [back to overview]Percentage of Subjects Achieving Blood Pressure Goals
NCT00880997 (4) [back to overview]Weeks of Abstinence
NCT00880997 (4) [back to overview]Cocaine Negative Urines
NCT00880997 (4) [back to overview]# of Participants That Completed the Study
NCT00880997 (4) [back to overview]Adverse Events
NCT01003886 (6) [back to overview]Change From Baseline in Diastolic BP at Week 4 and Week 12
NCT01003886 (6) [back to overview]Number of Participants With Adverse Events (AEs)
NCT01003886 (6) [back to overview]Percentage of Participants With Postural Hypotension
NCT01003886 (6) [back to overview]Change From Baseline in Systolic BP at Week 4 and Week 12
NCT01003886 (6) [back to overview]Percent Change From Baseline in the International Prostate Symptom (IPSS) Total Score at Week 4 and Week 12
NCT01003886 (6) [back to overview]Percent Change From Baseline in the IPSS Quality of Life (QoL) Score at Week 4 and Week 12
NCT01145183 (2) [back to overview]Adverse Events
NCT01145183 (2) [back to overview]Percentage of Cocaine Positive Urine Toxicology
NCT01371851 (1) [back to overview]Change in Psychostimulant-positive Urines Over Time
NCT01661621 (8) [back to overview]The International Prostate Symptom Score (IPSS) Questionnaires After the Treatment Day
NCT01661621 (8) [back to overview]The Global Response Assessment (GRA) After the Treatment Day
NCT01661621 (8) [back to overview]The International Prostate Symptom Score (IPSS) Quality of Life (QoL) Score After the Treatment Day
NCT01661621 (8) [back to overview]The IPSS Subscore (IPSS Storage) Questionnaires After the Treatment Day
NCT01661621 (8) [back to overview]The IPSS Subscore (IPSS Voiding) Questionnaires After the Treatment Day
NCT01661621 (8) [back to overview]The Maximum Flow Rate (Qmax) After the Treatment Day
NCT01661621 (8) [back to overview]The Postvoid Residual Volume (PVR) After the Treatment Day
NCT01661621 (8) [back to overview]The Voided Volume After the Treatment Day
NCT01678313 (6) [back to overview]Change From Baseline in the IPSS Subscore (IPSS Storage) Questionnaires
NCT01678313 (6) [back to overview]Change From Baseline in the IPSS Subscore (IPSS Voiding) Questionnaires
NCT01678313 (6) [back to overview]Change From Baseline in the Maximum Flow Rate (Qmax)
NCT01678313 (6) [back to overview]Change From Baseline in the Serum Prostate Specific Antigen (PSA) Level
NCT01678313 (6) [back to overview]Change From Baseline in the International Prostate Symptom Score (IPSS) Questionnaires
NCT01678313 (6) [back to overview]Change From Baseline in the Void Volume (VV)
NCT01730846 (2) [back to overview]Latency (Min) to Initiate Ad-lib Smoking Session
NCT01730846 (2) [back to overview]Number of Cigarettes Smoked During Ad-lib Session
NCT01798992 (3) [back to overview]Improvement in Left Ventricular Ejection Fraction (LVEF) at 12 Months
NCT01798992 (3) [back to overview]Improvement in LVEF at 3 Months
NCT01798992 (3) [back to overview]Composite of All-cause Mortality, Need for Heart Transplant or Need for Ventricular Assist Device.
NCT01953432 (1) [back to overview]Percentage of Cocaine-positive Urines
NCT02500602 (3) [back to overview]Time Line Follow Back (TLFB)
NCT02500602 (3) [back to overview]PTSD Checklist (PCL-5)
NCT02500602 (3) [back to overview]Clinician Administered PTSD Scale
NCT02989493 (2) [back to overview]Number of Participants Reporting Any Heavy Drinking Days
NCT02989493 (2) [back to overview]Startle Potentiation During Stress Reactivity Task
NCT03176693 (5) [back to overview]Hemodynamic Instability
NCT03176693 (5) [back to overview]Morbidity as Assessed by Occurrence of Adverse Events
NCT03176693 (5) [back to overview]Mortality
NCT03176693 (5) [back to overview]Participants Admitted to Post-operative Intensive Care Unit (ICU)
NCT03176693 (5) [back to overview]Daily Cost of Drug

"Number of Participants Who Achieved of BP, HbA1c and Total, HDL and LDL Cholesterol Goals at the End of Intervention Phase"

Achievement of targets at end of intervention was performed applying generalized estimating equation (GEE) models, further adjusting for baseline values as covariate. (NCT00535925)
Timeframe: 13 years

InterventionParticipants (Count of Participants)
Standard of Care (SoC) Therapy150
Multifactorial Intensified Therapy191

[back to top]

"Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)"

number of MACEs in the two groups are reported. In addition, The primary endpoint was analyzed with event curves for the time-to-first event based on Kaplan-Meier analysis. Cox regression model was used to calculate hazard ratio (HR) and 95% Confidence Interval (CI). Due to the cluster randomized study design, a Cox shared-frailty model was fitted. multivariable model was adjusted for selected potential confounders: age, sex, systolic blood pressure (SBP), hemoglobin, estimated glomerular filtration rate (eGFR), albuminuria, HbA1c, total cholesterol and triglycerides (log-scaled) to reduce risk of bias. (NCT00535925)
Timeframe: 4 years (in the case the number of events needed by sample size is not reached at the expected 4-year time frame, primary end point will be assessed after the follow-up phase)

InterventionParticipants (Count of Participants)
Conventional Therapy146
Intensified Therapy116

[back to top]

Percentage of Subjects Achieving Blood Pressure Goals

Percentage of subjects who achieved JNC-VII defined blood pressure goals. (NCT00661895)
Timeframe: 3 month intervals

Interventionpercentage of participants (Number)
Intervention81
Control57

[back to top]

Weeks of Abstinence

Percentage of participants achieving 2 or more consecutive weeks of abstinence (NCT00880997)
Timeframe: throughout the study - up to 17 weeks

Interventionpercentage of participants (Number)
DOX-slow Group0
DOX-fast Group44
Placebo7

[back to top]

Cocaine Negative Urines

cocaine urine toxicology samples were obtained thrice weekly and tested for the presence of the cocaine metabolite, benzoylecgonine (NCT00880997)
Timeframe: throughout the study - up to 17 weeks

Interventionpercentage of cocaine-negative urines (Number)
DOX-slow Group10
DOX-fast Group35
Placebo14

[back to top]

# of Participants That Completed the Study

Retention (NCT00880997)
Timeframe: throughout the study - up to 17 weeks

InterventionParticipants (Count of Participants)
DOX-slow Group6
DOX-fast Group6
Placebo5

[back to top]

Adverse Events

(NCT00880997)
Timeframe: throughout study - upto 17 weeks

Interventionevents (Number)
DOX-slow Group26
DOX-fast Group9
Placebo23

[back to top]

Change From Baseline in Diastolic BP at Week 4 and Week 12

Values at Week 4 and Week 12 minus value at baseline. (NCT01003886)
Timeframe: Baseline through Week 12

InterventionmmHg (Mean)
Change at Week 4 (n=816)Change at Week 12 (n=583)
Doxazosin GITS-1.50-2.40

[back to top]

Number of Participants With Adverse Events (AEs)

Any untoward medical occurrence in a participant who received study drug was considered an AE, without regard to possibility of causal relationship. (NCT01003886)
Timeframe: Baseline up to Week 13 (7 days after last dose)

InterventionParticipants (Number)
Doxazosin GITS14

[back to top]

Percentage of Participants With Postural Hypotension

Postural or orthostatic hypotension is a medical condition where blood pressure falls rapidly after the body changes position most commonly occurring after standing up after sitting for long periods of time. (NCT01003886)
Timeframe: Baseline up to Week 13 (7 days after last dose)

InterventionPercentage of participants (Number)
Doxazosin GITS0.3

[back to top]

Change From Baseline in Systolic BP at Week 4 and Week 12

Values at Week 4 and Week 12 minus value at baseline. (NCT01003886)
Timeframe: Baseline through Week 12

InterventionmmHg (Mean)
Change at Week 4 (n=816)Change at Week 12 (n=583)
Doxazosin GITS-3.80-5.70

[back to top]

Percent Change From Baseline in the International Prostate Symptom (IPSS) Total Score at Week 4 and Week 12

The IPSS total score is obtained by combining the scores of the responses to 1 through 7 component questions all of which were on a 6 point likert scale. Each question is scored from 0-5 for an IPSS range of 0-35 points where 0 = best possible score to 35 = worst possible score. (NCT01003886)
Timeframe: Baseline, Week 4 and Week 12

InterventionUnits on a scale (Mean)
Baseline (n=962)Percent change at Week 4 (n=889)Percent change at Week 12 (n=637)Percent change at Week 12 (LOCF) (n=934)
Doxazosin GITS22.30-44.90-65.10-61.40

[back to top]

Percent Change From Baseline in the IPSS Quality of Life (QoL) Score at Week 4 and Week 12

The IPSS QoL Score is obtained by assessment of a single QoL question on a 7-point likert scale which was scored on a scale of 0-6 where 0 = best possible score to 6 = worst possible score. (NCT01003886)
Timeframe: Baseline, Week 4 and Week 12

InterventionUnits on a scale (Mean)
Baseline (n=965)Percent change at Week 4 (n=892)Percent change at Week 12 (n=636)Percent change at Week 12 (LOCF) (n=936)
Doxazosin GITS4.20-44.60-64.10-60.50

[back to top]

Adverse Events

Adverse effects were closely monitored during each clinic visit throughout this trial. Vital signs including blood pressure (both pre-medication and post-medication) were measured and documented as were concomitant medications. (NCT01145183)
Timeframe: Pre- and post study medication

Interventionevents (Number)
Doxazosin0
Placebo0

[back to top]

Percentage of Cocaine Positive Urine Toxicology

Cocaine positive urines (NCT01145183)
Timeframe: 2 weeks blocks throughout study

,,,
Interventionpercentage of positive urines (Number)
Weeks 1-2Weeks 3-4Weeks 5-6Weeks 7-8Weeks 9-10Weeks 11-12
Doxazosin (AA Genotype)88.688.684.975.586.382.8
Doxazosin (AT/TT Genotype)85.684.768.070.361.967.3
Placebo (AA Genotype)75.782.884.977.280.681.2
Placebo (AT/TT Genotype)75.984.795.7100.097.0100.0

[back to top]

Change in Psychostimulant-positive Urines Over Time

Urine samples positive for methamphetamine or cocaine via twice-weekly urine drug screens. Weekly urine results data were averaged within subjects and the mean proportion across subjects within each group was calculated for graphic representation. (NCT01371851)
Timeframe: twice-weekly urine samples (8 weeks)

,
Interventionproportion of psychostimulant-pos urines (Mean)
Week 1 (N=10, 11)Week 2 (N=7, 8)Week 3 (N=6, 5)Week 4 (N=6, 4)Week 5 (N=4, 4)Week 6 (N=4, 3)Week 7 (N=4, 3)Week 8 (N=3, 2)
Doxazosin.6.79.58.75.5.631.83
Placebo.41.25.4.5.2500.25

[back to top]

The International Prostate Symptom Score (IPSS) Questionnaires After the Treatment Day

"Efficacy:~Using the total International Prostate Symptom Score (IPSS) to compare the efficacy in Group 1 and Group 2 from baseline to 1 month.~The International Prostate Symptom Score (IPSS) is an 7 symptom questions including 4 voiding questions (IPSS-voiding), 3 storage questions (IPSS-Storage) The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always.~Total IPSS score = IPSS-voiding + IPSS-Storage Rang = 0 to 35 (asymptomatic to very symptomatic). Mild = 0 to 7; Moderate = 8 to 19; Severe = 20 to 35~Safety:~Systemic adverse events such as difficult urination, dry mouth, blurred vision, constipation, dry eye, dizziness, or general weakness" (NCT01661621)
Timeframe: Baseline and 1 month

,
Interventionunits on a scale (Mean)
Baseline1 month
Group 114.811.2
Group 218.010.8

[back to top]

The Global Response Assessment (GRA) After the Treatment Day

"Efficacy Using global response assessment (GRA) to compare the efficacy in Group 1 and Group 2 from baseline to 1month.~The global response assessment on a 6-point scale ranging from 1 No problems at all to 6 Many severe problems.~Changes of the global response assessment (GRA) improved or reduction by 1 points.~Change = Baseline minus Month 1 value~Safety:~Systemic adverse events such as difficult urination, dry mouth, dry eye, blurred vision, constipation, dizziness or general weakness" (NCT01661621)
Timeframe: 1 month after initial treatment

,
Interventionparticipants (Number)
GRA≥1GRA<1
Group 18927
Group 221861

[back to top]

The International Prostate Symptom Score (IPSS) Quality of Life (QoL) Score After the Treatment Day

"Efficacy:~Using the the the International Prostate Symptom Score (IPSS) quality of life (QoL) score to compare the efficacy in Group 1 and Group 2 from baseline to 1month.~The IPSS quality of life question score on a 7-point scale ranging from 0 Delighted to 6 Terrible.~IPSS-QoL ranges 0 to 6 (Delighted to Terrible)~Safety:~Systemic adverse events such as difficult urination, dry mouth, blurred vision, constipation, dry eye, dizziness, or general weakness" (NCT01661621)
Timeframe: Baseline and 1 month

,
Interventionunits on a scale (Mean)
Baseline1 month
Group 13.912.82
Group 23.882.82

[back to top]

The IPSS Subscore (IPSS Storage) Questionnaires After the Treatment Day

"Efficacy:~Using the the IPSS subscore (IPSS Storage) to compare the efficacy in Group 1 and Group 2 from baseline to 1 month.~The IPSS subscore (IPSS Storage) is a 3 symptom questions. The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.~The total IPSS Storage score can therefore range from 0 to 15 (asymptomatic to very symptomatic).~Safety:~Systemic adverse events such as difficult urination, dry mouth, blurred vision, constipation, dry eye, dizziness, or general weakness" (NCT01661621)
Timeframe: Baseline and 1 month

,
Interventionunits on a scale (Mean)
Baseline1 month
Group 19.516.40
Group 25.704.31

[back to top]

The IPSS Subscore (IPSS Voiding) Questionnaires After the Treatment Day

"Efficacy:~Using the the IPSS subscore (IPSS Voiding) questionnaires to compare the efficacy in Group 1 and Group 2 from baseline to 1 month.~The IPSS subscore (IPSS Voiding) questionnaires is a 4 symptom questions. The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.~The total IPSS Voiding score can therefore range from 0 to 20 (asymptomatic to very symptomatic).~Safety:~Systemic adverse events such as difficult urination, dry mouth, blurred vision, constipation, dry eye, dizziness, or general weakness" (NCT01661621)
Timeframe: Baseline and 1 month

,
Interventionunits on a scale (Mean)
Baseline1 month
Group 15.314.84
Group 212.36.49

[back to top]

The Maximum Flow Rate (Qmax) After the Treatment Day

"Efficacy:~Net change used the the maximum flow rate (Qmax) in Group 1 and Group 2 from baseline to 1 month.~Safety:~Systemic adverse events such as difficult urination, dry mouth, blurred vision, constipation, dry eye, dizziness, or general weakness" (NCT01661621)
Timeframe: Baseline and 1 month

,
InterventionmL/s (Mean)
Baseline1 month
Group 113.113.6
Group 211.413.6

[back to top]

The Postvoid Residual Volume (PVR) After the Treatment Day

"Efficacy:~Net change used the the postvoid residual volume (PVR) in Group 1 and Group 2 from baseline to 1 month.~Safety:~Systemic adverse events such as difficult urination, dry mouth, blurred vision, constipation, dry eye, dizziness, or general weakness" (NCT01661621)
Timeframe: Baseline and 1 month

,
InterventionmL (Mean)
Baseline1 month
Group 150.160.4
Group 253.942.9

[back to top]

The Voided Volume After the Treatment Day

"Efficacy:~Net change used the the voided volume in Group 1 and Group 2 from baseline to 1 month.~Safety:~Systemic adverse events such as difficult urination, dry mouth, blurred vision, constipation, dry eye, dizziness, or general weakness" (NCT01661621)
Timeframe: Baseline and 1 month

,
InterventionmL (Mean)
Baseline1 month
Group 1212.5231.6
Group 2244.0268.3

[back to top]

Change From Baseline in the IPSS Subscore (IPSS Storage) Questionnaires

"Efficacy:~Change from Baseline in the IPSS Storage from baseline and 3 months The IPSS subscore (IPSS Storage) is a 3 symptom questions. The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.~The total IPSS Storage score can therefore range from 0 to 15 (asymptomatic to very symptomatic).~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment

,
Interventionunits on a scale (Mean)
Baseline3 monthsChange
Control Group6.064.01-2.05
Study Group5.593.09-2.5

[back to top]

Change From Baseline in the IPSS Subscore (IPSS Voiding) Questionnaires

"Efficacy:~Change from Baseline in the IPSS Voiding from baseline and 3 months. The IPSS subscore (IPSS Voiding) questionnaires is a 4 symptom questions. The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.~The total IPSS Voiding score can therefore range from 0 to 20 (asymptomatic to very symptomatic).~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment

,
Interventionunits on a scale (Mean)
Baseline3 monthsChange
Control Group5.543.45-2.09
Study Group7.553.84-3.71

[back to top]

Change From Baseline in the Maximum Flow Rate (Qmax)

"Efficacy:~Change from Baseline in the maximum flow rate (Qmax) from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment

,
InterventionmL/s (Mean)
Baseline3 monthsChange
Control Group10.011.91.9
Study Group12.212.2-0.09

[back to top]

Change From Baseline in the Serum Prostate Specific Antigen (PSA) Level

"Efficacy:~Change from Baseline in the serum PSA level from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment

,
Interventionng/mL (Mean)
Baseline3 monthsChange
Control Group15.213.5-1.70
Study Group10.89.42-1.43

[back to top]

Change From Baseline in the International Prostate Symptom Score (IPSS) Questionnaires

"Efficacy:~Change from Baseline in the International Prostate Symptom Score (IPSS) from baseline and 3 months The International Prostate Symptom Score (IPSS) is an 7 symptom questions including 4 voiding questions (IPSS Voiding), 3 storage questions (IPSS Storage) The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always.~Total IPSS score = IPSS voiding + IPSS Storage Rang = 0 to 35 (asymptomatic to very symptomatic). Mild = 0 to 7; Moderate = 8 to 19; Severe = 20 to 35~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment

,
Interventionunits on a scale (Mean)
Baseline3 monthsChange
Control Group12.07.70-4.31
Study Group13.16.45-6.63

[back to top]

Change From Baseline in the Void Volume (VV)

"Efficacy:~Change from Baseline in the Void Volume (VV) from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment

,
InterventionmL (Mean)
Baseline3 monthsChange
Control Group17523155.7
Study Group259227-32.3

[back to top]

Latency (Min) to Initiate Ad-lib Smoking Session

Latency to start smoking in the stress and neutral ad-lib smoking lab sessions. Subjects had the opportunity to delay smoking for 50 minutes (delay period). Once the subject decides to smoke, the 1 hour ad-lib smoking session begins. They can chose to smoke as little or as much as they wish. (NCT01730846)
Timeframe: 0 up to 50 minutes (Delay Period)

,,
Interventionminutes (Mean)
StressNeutral
4mg/Day32.12826.790
8mg/Day27.55723.776
Placebo11.30423.474

[back to top]

Number of Cigarettes Smoked During Ad-lib Session

"Number of cigarettes smoked during the stress and neutral ad-lib smoking period.~Once the subject decides to smoke (delay period), the 1 hour ad-lib smoking period begins. They can chose to smoke as little or as much as they wish." (NCT01730846)
Timeframe: 60 minutes (ad-lib smoking period)

,,
Interventionnumber of cigarettes (Mean)
StressNeutral
4mg/Day1.8901.866
8mg/Day1.8131.688
Placebo3.3312.139

[back to top]

Improvement in Left Ventricular Ejection Fraction (LVEF) at 12 Months

The primary clinical outcome will be LVEF response at 12 months defined as an improvement in LVEF of ≥ 8% at 12 months or if not available, ≥5% at 3 months in the absence of an adverse clinical outcome. Data are not presented for non-failing controls, who only went baseline evaluation and did not undergo treatment, given that they did not have heart failure. (NCT01798992)
Timeframe: 12 months

InterventionLVEF responders (Number)
Metoprolol Succinate12
Metoprolol Succinate + Doxazosin10
Carvedilol9

[back to top]

Improvement in LVEF at 3 Months

A secondary outcome will be LVEF response at 3 months, defined as an improvement of ≥ 5% Data are not presented for non-failing controls, who only went baseline evaluation and did not undergo treatment, given that they did not have heart failure. (NCT01798992)
Timeframe: 3 months

InterventionLVEF responders (Number)
Metoprolol Succinate16
Metoprolol Succinate + Doxazosin10
Carvedilol10

[back to top]

Composite of All-cause Mortality, Need for Heart Transplant or Need for Ventricular Assist Device.

Clinical status at 18 months will be assessed at time of study completion, specifically for the composite outcome of all-cause mortality, need for heart transplant, or need for ventricular assist device. Outcomes are not presented for non-failing controls, who only went baseline evaluation and did not undergo treatment, given that they did not have heart failure. (NCT01798992)
Timeframe: 18 months

Interventionparticipants (Number)
Metoprolol Succinate1
Metoprolol Succinate + Doxazosin0
Carvedilol0

[back to top]

Percentage of Cocaine-positive Urines

Over period of 12 weeks with 43 participants total (Doxazosin group = 22; Placebo group = 21), the overall percentage of cocaine positive urines per treatment group (NCT01953432)
Timeframe: Up to 12 weeks, or for the duration of the participant's involvement in the study

Interventionpercentage of cocaine-positive urines (Number)
Doxazosin67.6
Placebo69

[back to top]

Time Line Follow Back (TLFB)

The TLFB obtains retrospective self-report of substance use by using a calendar and memory prompts to stimulate recall (Sobell & Sobell, 1992). Quantity and frequency assessments are made using this instrument (e.g., total number of standard drink units, percent of days using) as well as abstinence (yes/no). TLFB yields consistently high test-retest correlations and correlates well with other self-reports and collateral reports (Sobell et al., 2003). The TLFB assesses frequency and amount of substance use over a pre-determined timeframe. TLFB data were collected throughout the trial, and the values reported here represent the TLFB data at end of treatment (week 12). (NCT02500602)
Timeframe: 12 Weeks

,
Interventionpercent (Mean)
percentage of days drinkingpercent heavy days drinking
Doxazosin53.737
Placebo48.138.6

[back to top]

PTSD Checklist (PCL-5)

The secondary PTSD outcome measure was the PTSD Checklist-5 (PCL-5; Weathers et al., 2013b). The PCL-5 is 20-item self-report measure that assesses the DSM-5 symptoms of PTSD using a severity rating Likert scale ranging from 0 to 4 that indicates the degree of distress across symptoms (0 = not at all to 4 = extremely). The overall score range is 0-80 (and combines the score for all 20 symptoms), with lower scores representing better outcomes (less severe PTSD symptomology). The PCL-5 was assessed at end of treatment (week 12). (NCT02500602)
Timeframe: 12 Weeks

Interventionscore on a scale (Mean)
Doxazosin47.3
Placebo46.9

[back to top]

Clinician Administered PTSD Scale

The primary PTSD outcome measure was the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5; Weathers et al., 2013). The CAPS-5 is a semi-structured interview that measures the DSM-5 symptoms of PTSD and requires the presence of at least one intrusion symptom, one avoidance symptom, two cognition and mood symptoms, and two arousal symptoms for a period of 1 month or more to reach diagnostic threshold. There are 20 symptom items and responses that are rated on a 5-point scale ranging from 0 (absent) to 4 (extreme/incapacitating), with a total PTSD symptom severity score of the sum of the 20 symptom items ranging from 0-80, and lower scores indicating better outcomes (or less severe PTSD symptomology). The CAPS-5 was assessed at end of treatment (week 12). (NCT02500602)
Timeframe: 12 Weeks

Interventionscore on a scale (Mean)
Doxazosin34.2
Placebo32.5

[back to top]

Number of Participants Reporting Any Heavy Drinking Days

"Timeline-followback (TLFB) was administered twice at 4 weeks and 8 weeks. Participants reported the number of drinks per day for each previous 30 day period. Any heavy drinking was scored yes if participant reported any days of heavy drinking (> 4/3 standard drinks for men/women) during the total 8 week assessment period; no if no heavy drinking was reported" (NCT02989493)
Timeframe: 8 weeks

InterventionParticipants (Count of Participants)
Doxazosin17
Placebo21

[back to top]

Startle Potentiation During Stress Reactivity Task

Startle potentiation is used to study anxiety and fear with No-shock, Predictable-shock, Unpredictable-shock (NPU) task; a common, well-validated laboratory stressor task. In the Predictable condition of the NPU task, shocks are 100 percent predictable and occur at a consistent, known time. In the Unpredictable condition of the NPU task, shocks are fully unpredictable. A higher score on startle potentiation means a higher stress reactivity response for the given condition. (NCT02989493)
Timeframe: 4 weeks

,
Interventionmicrovolts (Mean)
Unpredictable startle potentiationPredictable startle potentiation
Doxazosin22.2526.22
Placebo20.7622.21

[back to top]

Hemodynamic Instability

"Proportion of operative time outside target thresholds: SBP >180 or <80; DBP > 90; MAP>150 or <50; HR>90.~Arterial line blood pressure measurements were extracted from the electronic medical record every 60 seconds." (NCT03176693)
Timeframe: Intraoperative, approximately 90 minutes

Interventionpercentage of total operative time (Median)
Phenoxybenzamine14
Doxazosin13

[back to top]

Morbidity as Assessed by Occurrence of Adverse Events

Morbidity will be graded by Clavien Classification of adverse events (NCT03176693)
Timeframe: Postoperatively during inpatient stay and during readmissions up to 30 days postoperatively

Interventionevents (Number)
Phenoxybenzamine0
Doxazosin0

[back to top]

Mortality

Death within 30 days of surgery (NCT03176693)
Timeframe: 30 days postoperatively

InterventionParticipants (Count of Participants)
Phenoxybenzamine0
Doxazosin0

[back to top]

Participants Admitted to Post-operative Intensive Care Unit (ICU)

(NCT03176693)
Timeframe: up to 30 days post-surgery

InterventionParticipants (Count of Participants)
Phenoxybenzamine2
Doxazosin1

[back to top]

Daily Cost of Drug

(NCT03176693)
Timeframe: Preoperative (2-3 weeks prior to surgery)

InterventionDollars (Median)
Phenoxybenzamine442.20
Doxazosin5.06

[back to top]